<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006781.pub3" GROUP_ID="VASC" ID="878706090613213819" MERGED_FROM="" MODIFIED="2015-11-17 17:17:25 +0000" MODIFIED_BY="Nicole Martin" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;APPENDIX A: FORMS&lt;/p&gt;&lt;p&gt;AMINOPHYLLINE FOR ASYSTOLIC CARDIAC ARREST IN ADULTS&lt;/p&gt;&lt;p&gt;CRITERIA FOR INCLUSION &lt;/p&gt;&lt;p&gt;Citation #___________&lt;br&gt;Reviewer: KH RG KM&lt;/p&gt;&lt;p&gt;Please assess the following questions for each paper. STOP WHEN THE STUDY FAILS TO MEET ONE INCLUSION CRITERION. The inclusion criteria are:&lt;/p&gt;&lt;p&gt;[1] DESIGN&lt;/p&gt;&lt;p&gt;[ ] Include randomized controlled clinical trials on adults.&lt;br&gt;[ ] Exclude all studies which are non-experimental cohort study, case-control study, before-after studies, case series, letters, reviews, etc.&lt;/p&gt;&lt;p&gt;[2] POPULATIONS&lt;/p&gt;&lt;p&gt;[ ] Include if patients were selected during resuscitation from asystolic cardiac arrest.&lt;br&gt;[ ] Include papers with patients =16 years of age&lt;br&gt;[ ] Exclude papers where the patients suffered traumatic or hypothermic cardiac arrest.&lt;br&gt;[ ] Exclude papers where the patients' rhythm is ventricular fibrillation, ventricular tachycardia or other tachydysrhythmia.&lt;/p&gt;&lt;p&gt;[3] INTERVENTIONS&lt;/p&gt;&lt;p&gt;[ ] Include all primary research in which patients were treated with aminophylline versus placebo as part of the resuscitation.&lt;br&gt;[ ] Exclude if use of aminophylline was not the primary research question or if aminophylline was not compared versus placebo. &lt;/p&gt;&lt;p&gt;[4] OUTCOMES&lt;/p&gt;&lt;p&gt;[ ] Include papers that report clinically relevant outcomes (i.e. return of spontaneous circulation, survival to admission, survival to discharge and neurological outcome).&lt;br&gt;[ ] Exclude all studies that do not report clinically relevant outcomes.&lt;/p&gt;&lt;p&gt;[5] FINAL DECISION&lt;br&gt;[ ] INCLUDED (meets inclusion criteria above)&lt;br&gt;[ ] NOT INCLUDED&lt;br&gt;[ ] CAN'T TELL (need more information from authors to make decision)&lt;br&gt;AMINOPHYLLINE FOR BRADYASYSTOLIC ARREST IN ADULTS&lt;/p&gt;&lt;p&gt;DATA ABSTRACTION FORM&lt;/p&gt;&lt;p&gt;The data abstraction form is currently under development.&lt;/p&gt;&lt;p&gt;POPULATION&lt;br&gt;Intervention (aminophylline) vs. Control (placebo):&lt;br&gt;N (number of patients)&lt;br&gt;Mean age (years)&lt;br&gt;Median age (years)&lt;br&gt;Age range (years)&lt;br&gt;Etiology of arrest?&lt;/p&gt;&lt;p&gt;DESIGN&lt;/p&gt;&lt;p&gt;Method of randomization:&lt;br&gt;________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________&lt;/p&gt;&lt;p&gt;DEFINITIONS&lt;/p&gt;&lt;p&gt;Definition of asystolic arrest:&lt;br&gt;________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________&lt;/p&gt;&lt;p&gt;Planned duration of resuscitation after administration of aminophylline: ______&lt;/p&gt;&lt;p&gt;Definition of neurologic outcome scale:&lt;br&gt;________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________&lt;/p&gt;&lt;p&gt;INTERVENTION&lt;/p&gt;&lt;p&gt;Dosage of aminophylline: ___________________&lt;/p&gt;&lt;p&gt;Intervention (aminophylline) vs. Control (placebo)&lt;br&gt;Time to administration (minutes)&lt;/p&gt;&lt;p&gt;OUTCOMES&lt;br&gt;Intervention (aminophylline) vs. Control (placebo):&lt;br&gt;ROSC &lt;br&gt;Admission to hospital&lt;br&gt;Survival to discharge&lt;br&gt;Neurologic outcome&lt;/p&gt;&lt;p&gt;&lt;br&gt;AMINOPHYLLINE FOR BRADYASYSTOLIC ARREST IN ADULTS&lt;/p&gt;&lt;p&gt;METHODOLOGICAL QUALITY ASSESSMENT&lt;/p&gt;&lt;p&gt;Citation # ___________&lt;/p&gt;&lt;p&gt;Reviewer: KH RG KM&lt;/p&gt;&lt;p&gt;Cochrane Heart Group Criteria for Quality Assessment&lt;/p&gt;&lt;p&gt;1) Method of assignment: Was the assignment truly randomized?&lt;br&gt;[ ] Grade A: Adequate randomization&lt;br&gt;[ ] Grade B: Uncertain&lt;br&gt;[ ] Grade C: Clearly inadequate randomization&lt;/p&gt;&lt;p&gt;2) Blinding: Were investigators and caregivers unaware of the treatment assignment?&lt;br&gt;[ ] Grade A: Adequate concealment&lt;br&gt;[ ] Grade B: Uncertain&lt;br&gt;[ ] Grade C: Clearly inadequate concealment&lt;/p&gt;&lt;p&gt;3) Control of selection bias: Were all study participants accounted for and analysis carried out in an intention to treat fashion?&lt;br&gt;[ ] Grade A: Adequate&lt;br&gt;[ ] Grade B: Uncertain&lt;br&gt;[ ] Grade C: Clearly inadequate&lt;/p&gt;" NOTES_MODIFIED="2015-11-17 17:15:16 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0606" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2015-11-17 17:17:25 +0000" MODIFIED_BY="Nicole Martin">
<TITLE>Aminophylline for bradyasystolic cardiac arrest in adults</TITLE>
<CONTACT MODIFIED="2015-11-17 17:17:25 +0000" MODIFIED_BY="Nicole Martin"><PERSON ID="8299953782E26AA200C1C7C43FDA966D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katrina</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Hurley</LAST_NAME><POSITION>Emergency Physician</POSITION><EMAIL_1>kfhurley@dal.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>IWK Health Centre</ORGANISATION><ADDRESS_1>5850/5980 University Ave</ADDRESS_1><ADDRESS_2>PO Box 9700</ADDRESS_2><CITY>Halifax</CITY><ZIP>B3K 6R8</ZIP><REGION>NS</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 902 470 8823</PHONE_1><FAX_1>+1 902 470 7248</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-11-17 17:17:25 +0000" MODIFIED_BY="Nicole Martin"><PERSON ID="8299953782E26AA200C1C7C43FDA966D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katrina</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Hurley</LAST_NAME><POSITION>Emergency Physician</POSITION><EMAIL_1>kfhurley@dal.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>IWK Health Centre</ORGANISATION><ADDRESS_1>5850/5980 University Ave</ADDRESS_1><ADDRESS_2>PO Box 9700</ADDRESS_2><CITY>Halifax</CITY><ZIP>B3K 6R8</ZIP><REGION>NS</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 902 470 8823</PHONE_1><FAX_1>+1 902 470 7248</FAX_1></ADDRESS></PERSON><PERSON ID="13890" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kirk</FIRST_NAME><LAST_NAME>Magee</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>kmagee@dal.ca</EMAIL_1><EMAIL_2>kmagee@hfx.eastlink.ca</EMAIL_2><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Dalhousie University</ORGANISATION><ADDRESS_1>Queen Elizabeth II Health Sciences Centre, Halifax Infirmary</ADDRESS_1><ADDRESS_2>1796 Summer Street</ADDRESS_2><CITY>Halifax</CITY><ZIP>B3H 3A7</ZIP><REGION>NS</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 902 473 8564</PHONE_1><PHONE_2>+1 902 431 0860</PHONE_2><FAX_1>+1 902 473 3617</FAX_1></ADDRESS></PERSON><PERSON ID="82A96D1082E26AA200C1C7C4B652F958" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Robert</FIRST_NAME><LAST_NAME>Green</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>greenrs@dal.ca</EMAIL_1><ADDRESS><DEPARTMENT>Co-appointments in Emergency Medicine and Critical Care</DEPARTMENT><ORGANISATION>Dalhousie Univeristy</ORGANISATION><ADDRESS_1>Room 377 Bethune Building, 1278 Tower Road</ADDRESS_1><CITY>Halifax</CITY><ZIP>B3H 2Y9</ZIP><REGION>NS</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 902 473 7921</PHONE_1><FAX_1>+1 902 473 3610</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-09-29 14:05:56 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="17" MONTH="11" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="11" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="11" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="8" YEAR="2013"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-08-25 10:15:15 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-08-25 10:15:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>No new studies were identified for inclusion. Our conclusion remain the same. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-07-26 13:15:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="11" YEAR="2014"/>
<DESCRIPTION>
<P>The search strategy was updated in November 2014. No new studies were found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-06-29 20:24:44 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-29 20:24:44 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Dalhousie University</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-11-17 17:15:16 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-09-29 08:04:06 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-11-28 03:28:51 +0000" MODIFIED_BY="[Empty name]">Aminophylline for cardiac arrest</TITLE>
<SUMMARY_BODY MODIFIED="2015-09-29 08:04:06 +0100" MODIFIED_BY="[Empty name]">
<P>Aminophylline is a drug that might help resuscitate patients in cardiac arrest when electrical activity is very slow or absent. Aminophylline may restore blood flow to the heart, improve electrical activity and make other drugs used in resuscitation more effective. We found five studies that included 1254 patients who had this type of cardiac arrest in the prehospital setting. Four of the five studies (1186 patients) were well-designed studies with low risk of bias. Although no adverse events were reported, aminophylline showed no advantage when it was added to the standard resuscitation practice of paramedics when compared with placebo in these patients. It is not known whether giving aminophylline sooner would be helpful.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-09-29 14:07:28 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-07-26 19:10:47 +0100" MODIFIED_BY="[Empty name]">
<P>In cardiac ischaemia, the accumulation of adenosine may lead to or exacerbate bradyasystole and diminish the effectiveness of catecholamines administered during resuscitation. Aminophylline is a competitive adenosine antagonist. Case studies suggest that aminophylline may be effective for atropine-resistant bradyasystolic arrest.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-07-26 19:12:01 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effects of aminophylline in the treatment of patients in bradyasystolic cardiac arrest, primarily survival to hospital discharge. We also considered survival to admission, return of spontaneous circulation, neurological outcomes and adverse events.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-09-29 14:07:28 +0100" MODIFIED_BY="[Empty name]">
<P>For this updated review, we searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, LILACS, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform in November 2014. We checked the reference lists of retrieved articles, reviewed conference proceedings, contacted experts and searched further using Google. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-07-26 19:17:17 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials comparing intravenous aminophylline with administered placebo in adults with non-traumatic, normothermic bradyasystolic cardiac arrest who were treated with standard advanced cardiac life support (ACLS).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-07-26 19:18:32 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently reviewed the studies and extracted the included data. We contacted study authors when needed. Pooled risk ratio (RR) was estimated for each study outcome. Subgroup analysis was predefined according to the timing of aminophylline administration.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-09-29 08:01:53 +0100" MODIFIED_BY="[Empty name]">
<P>We included five trials in this analysis, all of which were performed in the prehospital setting. The risk of bias was low in four of these studies (n = 1186). The trials accumulated 1254 participants. Aminophylline was found to have no effect on survival to hospital discharge (risk ratio (RR) 0.58, 95% confidence interval (CI) 0.12 to 2.74) or on secondary survival outcome (survival to hospital admission: RR 0.92, 95% CI 0.61 to 1.39; return of spontaneous circulation: RR 1.15, 95% CI 0.89 to 1.49). Survival was rare (6/1254), making data about neurological outcomes and adverse events quite limited. The planned subgroup analysis for early administration of aminophylline included 37 participants. No one in the subgroup survived to hospital discharge.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-07-26 19:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>The prehospital administration of aminophylline in bradyasystolic arrest is not associated with improved return of circulation, survival to admission or survival to hospital discharge. The benefits of aminophylline administered early in resuscitative efforts are not known.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-10-07 02:04:57 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-10-07 02:04:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Description of the condition</HEADING>
<P>The incidence of out-of-hospital cardiac arrest is estimated to be 58.9 to 78.8 per 100,000 person-years (<LINK REF="REF-Hasegawa-2013" TYPE="REFERENCE">Hasegawa 2013</LINK>). People suffering a cardiac arrest may have complete loss of cardiac electrical activity and heart rhythm (asystole), a slow heart rhythm but no cardiac output or a disorganised rhythm (ventricular fibrillation). Bradyasystole, defined as the absence of cardiac electrical activity confirmed in more than one lead or pulseless electrical activity at a rate of less than 60 beats per minute, is the most commonly recorded initial rhythm in cardiac arrest (<LINK REF="REF-Herlitz-1994" TYPE="REFERENCE">Herlitz 1994</LINK>; <LINK REF="REF-Sedgwick-1994" TYPE="REFERENCE">Sedgwick 1994</LINK>; <LINK REF="REF-Steill-2004" TYPE="REFERENCE">Steill 2004</LINK>; <LINK REF="REF-Vaillancourt-2004" TYPE="REFERENCE">Vaillancourt 2004</LINK>). Fewer than 10% of patients suffering cardiac arrest (all rhythms) survive to discharge from hospital (<LINK REF="REF-Kette-1998" TYPE="REFERENCE">Kette 1998</LINK>; <LINK REF="REF-Hasegawa-2013" TYPE="REFERENCE">Hasegawa 2013</LINK>). Overall survival from 'non-shockable' rhythms is estimated to be less than 3% (<LINK REF="REF-Thomas-2013" TYPE="REFERENCE">Thomas 2013</LINK>). The outlook for asystole, in particular, is more dismal, with fewer than 1% surviving (<LINK REF="REF-Steill-2004" TYPE="REFERENCE">Steill 2004</LINK>; <LINK REF="REF-Vaillancourt-2004" TYPE="REFERENCE">Vaillancourt 2004</LINK>). Interventions to improve outcomes in this group may have a significant impact in terms of lives saved.</P>
<P>Clinical trials on interventions in cardiac arrest have been hindered by variability in data definitions and outcome measures. This has been addressed in part by the Utstein style reporting template for out-of-hospital cardiac arrest from the International Liaison Committee on Resuscitation (ILCOR) (<LINK REF="REF-Cummins-1991" TYPE="REFERENCE">Cummins 1991</LINK>; <LINK REF="REF-Cummins-1997" TYPE="REFERENCE">Cummins 1997</LINK>; <LINK REF="REF-Jacobs-2004" TYPE="REFERENCE">Jacobs 2004</LINK>). These guidelines represent an international consensus on the definitions and core data needed to report and study resuscitation for both research purposes and clinical benchmarking. It is interesting to note that ILCOR could not reach a consensus on the definition of asystole or bradyasystole (<LINK REF="REF-Jacobs-2004" TYPE="REFERENCE">Jacobs 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Description of the intervention</HEADING>
<P>Aminophylline is a complex of theophylline and ethylenediamine. Aminophylline's active metabolite is theophylline, and pharmacokinetic data quoted in product monographs reference the active metabolite rather than the parent compound. These methylxanthines are metabolised by the liver with about 10% excreted (unchanged) by the kidneys (Micromedex Solutions). The average plasma half-life is 7 to 9 hours in healthy non-smoking adults and 4 to 5 hours in adult smokers (<LINK REF="REF-Rudusky-2005" TYPE="REFERENCE">Rudusky 2005</LINK>). The median half-life in septic patients is prolonged (18.8 hours). The specific pharmacokinetics of aminophylline administered in the setting of cardiac arrest is not known.</P>
<P>Methylxanthines are known to have numerous drug interactions. Prolonged clearance of theophylline has been particularly reported with cimetidine, macrolide antibiotics and ciprofloxacin. Adverse effects in the setting of cardiac arrest have not been reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">How the intervention might work</HEADING>
<P>Adenosine is an endogenous nucleotide that plays a role in the regulation of myocardial oxygen supply and demand (<LINK REF="REF-Mader-2000" TYPE="REFERENCE">Mader 2000</LINK>). In periods of cellular hypoxia, production of adenosine is increased, leading to accumulation in ischaemic cardiac muscle. In what is believed to be a cardioprotective mechanism, adenosine acts to increase oxygen supply through coronary vasodilation and to diminish oxygen demand by reducing intrinsic pacemaker activity, blocking conduction at the atrioventricular (AV) node and attenuating the response to catecholamines (<LINK REF="REF-Schrader-1977" TYPE="REFERENCE">Schrader 1977</LINK>; <LINK REF="REF-Dobson-1983" TYPE="REFERENCE">Dobson 1983</LINK>; <LINK REF="REF-Wesley-1989" TYPE="REFERENCE">Wesley 1989</LINK>; <LINK REF="REF-Malcolm-1993" TYPE="REFERENCE">Malcolm 1993</LINK>; <LINK REF="REF-Belardinelli-1995" TYPE="REFERENCE">Belardinelli 1995</LINK>; <LINK REF="REF-Mader-2000" TYPE="REFERENCE">Mader 2000</LINK>). These actions in the setting of cardiac ischaemia may lead to bradycardia or bradyasystole resistant to atropine, as it is independent of parasympathetic tone. Furthermore, adenosine diminishes the effectiveness of exogenous catecholamines (<LINK REF="REF-Belardinelli--1989" TYPE="REFERENCE">Belardinelli 1989</LINK>; <LINK REF="REF-Visentin-1990" TYPE="REFERENCE">Visentin 1990</LINK>).</P>
<P>Aminophylline is a competitive nonspecific antagonist of adenosine that enhances cardiac response to beta-agonists and stimulates endogenous catecholamine release (<LINK REF="REF-Rudusky-2005" TYPE="REFERENCE">Rudusky 2005</LINK>). The pathophysiology of bradyasystolic arrest suggests that intravenous aminophylline may be a promising therapy for patients in whom atropine is ineffective (<LINK REF="REF-Mader-2000" TYPE="REFERENCE">Mader 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Why it is important to do this review</HEADING>
<P>Although reported cases of successful resuscitation with aminophylline generated enthusiasm for this therapy, little has changed with respect to its use in standard care in the last 20 years (<LINK REF="REF-Viskin-1993" TYPE="REFERENCE">Viskin 1993</LINK>; <LINK REF="REF-Perouansky-1998" TYPE="REFERENCE">Perouansky 1998</LINK>; <LINK REF="REF-Lee-2000" TYPE="REFERENCE">Lee 2000</LINK>; <LINK REF="REF-Neumar-2010" TYPE="REFERENCE">Neumar 2010</LINK>). The adult advanced cardiac life support (ACLS) guidelines in 2010 did not even mention aminophylline (<LINK REF="REF-Neumar-2010" TYPE="REFERENCE">Neumar 2010</LINK>). To date, there have been no meta-analyses of randomised controlled trials on the use of aminophylline in bradyasystolic arrest. This systematic review of randomised controlled trials compares intravenous aminophylline with placebo in participants with bradyasystolic cardiac arrest to determine whether evidence is available to justify adopting aminophylline as a standard therapy in these patients. The low event rate (survival to hospital discharge) means that a large study or a large meta-analysis is needed to answer this question. We will update this study on an ongoing basis to find new studies.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-07-27 05:26:00 +0100" MODIFIED_BY="Dolores Matthews">
<P>To determine the effects of aminophylline in the treatment of patients in bradyasystolic cardiac arrest, primarily survival to hospital discharge. We also considered survival to admission, return of spontaneous circulation, neurological outcomes and adverse events.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-10-07 01:50:08 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-10-07 01:50:08 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-07-27 05:26:50 +0100" MODIFIED_BY="Katrina Hurley">
<P>All randomised controlled trials comparing intravenous aminophylline with the administration of placebo.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-07-27 14:20:17 +0100" MODIFIED_BY="Katrina Hurley">
<P>Adult participants (16 years of age or older) with non-traumatic, normothermic bradyasystolic cardiac arrest. Bradyasystole must have been present at the time of administration of aminophylline.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-10-07 01:50:08 +0100" MODIFIED_BY="[Empty name]">
<P>Bradyasystole was defined as the absence of cardiac electrical activity as confirmed in more than one lead or pulseless electrical activity at a rate of fewer than 60 beats per minute. All interventions that compare intravenous aminophylline with placebo during resuscitation from bradyasystolic cardiac arrest were studied, in addition to standard ACLS. Depending on the preceding cardiac rhythms, standard care may include atropine, epinephrine, vasopressin or a combination of these. We did not analyse the combinations of drugs administered along with aminophylline. However, we planned an a priori subgroup to assess whether aminophylline was administered early or late during resuscitation.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-09-29 08:24:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome.</P>
<UL>
<LI>Survival to hospital discharge.</LI>
</UL>
<P>Secondary outcomes.</P>
<UL>
<LI>Return of spontaneous circulation.</LI>
<LI>Survival to hospital admission (survived event).</LI>
<LI>Neurological outcome.</LI>
<LI>Adverse events.</LI>
</UL>
<P>Survival to hospital discharge, survival to hospital admission and return of spontaneous circulation were defined according to the Utstein style guidelines and templates (<LINK REF="REF-Jacobs-2004" TYPE="REFERENCE">Jacobs 2004</LINK>).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-09-29 14:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>We carried out a comprehensive search to identify relevant trials, irrespective of language and publication status.</P>
<P>We initially searched the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>(Issue 4, 2009), MEDLINE, EMBASE, CINAHL and LILACS on 26 November 2009 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="REF-Hurley-2007" TYPE="REFERENCE">Hurley 2007</LINK>; <LINK REF="REF-Hurley-2013" TYPE="REFERENCE">Hurley 2013</LINK>). We performed new searches of CENTRAL, MEDLINE, EMBASE and CINAHL in November 2014 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We also searched ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>), using the terms 'cardiac arrest' OR 'asystole' OR 'bradyasystole' as the condition and 'aminophylline' OR 'adenosine antagonist' as the intervention.</P>
<P>We used similar terms to search the grey literature through Google Scholar, the Canada Institute for Scientific and Technical Information (CISTI) Catalogue and the British Library Public Catalogue. We reviewed reference lists of all available primary studies and review articles to identify potentially relevant citations. We also contacted authors of primary studies to inquire about other published or unpublished trials known to them. We contacted scientific advisors for the pharmaceutical companies that manufacture aminophylline (Omega Laboratories and Hospira Healthcare Corporation) for any unpublished results on the use of aminophylline in asystolic arrest. Finally, we reviewed reference lists of relevant trials and review articles as well as conference proceedings from the Canadian Association of Emergency Physicians, the American College of Emergency Physicians, the Society for Academic Emergency Medicine and the American Heart Association (January 1997 to December 2012) and from the European Society of Cardiology (January 2005 to December 2012).</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-09-29 14:12:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-09-29 08:40:11 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (KFH, RG) screened the full list of titles and abstracts retrieved from the searches, selecting all trials that appeared relevant on the basis of title, abstract and MeSH headings. These two review authors independently reviewed the full-text articles identified as potentially relevant to select trials for inclusion. We resolved disagreements by discussion or by third party adjudication (KM).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-09-29 11:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (KFH, KM) independently extracted data from the trials and entered them into Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). Data extraction included the following items.</P>
<UL>
<LI>Population: age, sex, aetiology of arrest, inclusion and exclusion criteria.</LI>
<LI>Intervention: dose and time to administration of aminophylline.</LI>
<LI>Control: definition of asystolic arrest, duration of resuscitation after administration of aminophylline, definition of neurological outcome.</LI>
<LI>Outcome: return of spontaneous circulation, survival to admission, survival to discharge, neurological outcome, adverse outcomes.</LI>
<LI>Design: method of randomisation.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-09-29 08:42:17 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (KFH, RG) assessed risk of bias using the criteria recommended by the<I> Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (low risk, high risk, unclear).</P>
<UL>
<LI>Selection: Was the assignment truly randomised? Was the allocation sequence concealed? (selection bias)</LI>
<LI>Blinding: Were investigators, participants and caregivers unaware of the treatment assignment? (detection bias and performance bias)</LI>
<LI>Losses to follow-up: Were all study participants accounted for and analyses carried out in an intention-to-treat fashion? (attrition bias)</LI>
<LI>Reporting: Were all outcomes reported? (reporting bias)</LI>
</UL>
<P>We were not blinded to the identity of study authors or study results.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-09-29 14:12:34 +0100" MODIFIED_BY="[Empty name]">
<P>We combined data in <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>. For dichotomous variables, individual and pooled statistics were calculated as risk ratios (RRs) with 95% confidence intervals (CIs). We used a fixed-effect model for data synthesis and assessed heterogeneity using the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). For continuous outcomes, we calculated individual and pooled statistics as mean differences (MDs) or standardised mean differences (SMDs) and 95% CIs using a random-effects model.</P>
</EFFECT_MEASURES>
<BIAS_ASSESSMENT MODIFIED="2015-09-29 14:12:46 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to carry out the statistical analyses on an intention-to-treat basis to deal with missing data from individual trials. The data were evaluated for publication bias using graphical and statistical methods. We checked for publication bias using a funnel plot. We assessed the effects of risk of bias in the included studies by using three criteria: method of assignment, blinding and losses to follow-up.<BR/>
</P>
</BIAS_ASSESSMENT>
<SUBGROUP_ANALYSIS MODIFIED="2015-09-29 08:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>We planned two subgroup analyses: comparison of results based on early administration of aminophylline using five minutes as the cut-off point between early and late administration. With respect to use of Utstein style reporting, we considered explicit mention of Utstein style reporting in the study or in correspondence with study authors.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-09-29 08:55:47 +0100" MODIFIED_BY="[Empty name]">
<P>Where significant heterogeneity (P &lt; 0.1) existed, we divided the groups based on our assessment of risk of bias (high versus low).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-09-29 14:24:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-09-29 14:24:42 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-09-29 14:24:42 +0100" MODIFIED_BY="[Empty name]">
<P>In our initial review in 2009, structured database searches yielded 285 records. Further online searches through Google and Google Scholar yielded an additional 21 records. After identifying and removing duplicates, we screened 264 records. We retrieved 22 articles for detailed review. Two authors excluded 14 articles: Nine were Chinese papers that were reported to be randomised trials yet on further inquiry were found not to be prospectively designed (<LINK REF="STD-Meng-2001" TYPE="STUDY">Meng 2001</LINK>; <LINK REF="STD-Ma-2003" TYPE="STUDY">Ma 2003</LINK>; <LINK REF="STD-Dong-2006" TYPE="STUDY">Dong 2006</LINK>; <LINK REF="STD-Fu-2006" TYPE="STUDY">Fu 2006</LINK>; <LINK REF="STD-Jin-2006" TYPE="STUDY">Jin 2006</LINK>; <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK>; <LINK REF="STD-Xiao-2006" TYPE="STUDY">Xiao 2006</LINK>; <LINK REF="STD-Shi-2007" TYPE="STUDY">Shi 2007</LINK>; <LINK REF="STD-Guo-2008" TYPE="STUDY">Guo 2008</LINK>); five articles reported mixed comparisons of aminophylline and epinephrine (<LINK REF="STD-Luo-2002" TYPE="STUDY">Luo 2002</LINK>; <LINK REF="STD-Wu-2002" TYPE="STUDY">Wu 2002</LINK>; <LINK REF="STD-Luo-2003" TYPE="STUDY">Luo 2003</LINK>; <LINK REF="STD-Shi-2008" TYPE="STUDY">Shi 2008</LINK>; <LINK REF="STD-Sun-2009" TYPE="STUDY">Sun 2009</LINK>). Two articles were conference abstracts reporting data that were also reported in full text (<LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>). See details in our <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>The updated search in November 2014 yielded 39 new records, all of which we screened and excluded. We did not retrieve any additional records for inclusion in this review update.</P>
<P>Five studies met inclusion criteria for this review (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>). One study, published in abstract form only, is awaiting further classification (<LINK REF="STD-Snell-2000" TYPE="STUDY">Snell 2000</LINK>). Despite repeated attempts to make contact with its authors, we were unable to garner enough additional methodological information to include any of its data in this review.</P>
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for the study flow diagram.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-09-29 14:16:07 +0100" MODIFIED_BY="[Empty name]">
<P>We included data from five studies in this meta-analysis, summarising each study's particular features in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>The five trials included only out-of-hospital arrests and took place in urban, prehospital settings in Canada (n = 971, one study), the United States (n = 215, three studies) and Germany (n = 68, one study). Two studies did not report the specific study period (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK>). The remaining studies were conducted from 1996 to 2003.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The studies focused on adult participants. <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK> excluded patients younger than 16 years, and each of Mader's studies excluded patients younger than 21 years (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>). <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK> did not specify the exclusion criteria in his published abstract, although communications with the author confirm that the trial excluded patients younger than 16 years. All trials excluded patients with suspected traumatic or hypothermic cardiac arrests. Most studies also excluded patients who were pregnant, using theophylline, known to have hypersensitivity to methylxanthines or known to have liver disease. <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK> further excluded patients who had evidence of haemorrhage or were on renal dialysis.</P>
<P>Mean age of included participants ranged from 65 to 76.8 years. Females represented a minority (377/1186), although this varied from 28.5% in <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK> to 45% in <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>. <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK> did not report these data.</P>
<P>Four studies reported data about the presumed cause of the cardiac arrest (<LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>). Three studies reported that suspected ischaemic cardiac events were the most common cause of the arrest, ranging from 64% to 82% (<LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>). <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK> reported their suspicion that 20.7% of participants had suffered a primary non-ischaemic cardiac event, but that most causes remained "uncertain."</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>All trials compared the administration of IV aminophylline with placebo as an adjunct to standard ACLS resuscitation in bradyasystolic cardiac arrest. Four studies used 250 mg doses of aminophylline, and one study used 240 mg doses (<LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK>). Four studies required failure of standard ACLS interventions for one to two minutes before the study medication was administered. One study administered aminophylline along with initial doses of epinephrine and atropine (<LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>). Mean time to arrival of the paramedic crew ranged from 5.3 to 9.3 minutes. Because of differences in reporting, it is difficult to comment on the time from the event to administration of aminophylline, although the time from arrival of paramedics to administration of aminophylline ranged from 11 to 16.6 minutes (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-09-29 09:19:19 +0100" MODIFIED_BY="[Empty name]">
<P>The assessed risk of bias for each study is detailed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. In general, the included studies were well-designed randomised, placebo-controlled trials. Random sequence generation was aided by computer (<LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>) or by an investigational drug service (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>). Use of matched syringes, provided by a third party, assisted with both blinding and allocation concealment (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>). Risks of performance bias, detection bias and attrition bias were low for four studies (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>). The degree of risk associated with randomisation, allocation, blinding and incomplete outcomes data for <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK> remains 'unclear' because the details about study methodology that were available in the published abstract and in the poster provided by the study's lead author were minimal. Further details about methodology could not be obtained from the study's lead author despite repeated attempts to make contact by email. The risk of selective reporting bias was deemed to be low in all studies (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>) because each study reported the outcomes expected from a cardiac arrest study, namely, return of spontaneous circulation, survival to admission, survival to discharge and neurological outcomes. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for a summary of risk of bias.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-09-29 14:16:50 +0100" MODIFIED_BY="[Empty name]">
<P>Few disagreements arose between review authors (KFH, RG) in assessing studies for inclusion, assessing risk of bias or extracting data, and they were readily resolved by discussion to reach consensus. With only five studies included in this systematic review, it is difficult to draw conclusions regarding the funnel plot. For example, only two studies included participants who experienced the primary outcome (survival to hospital discharge). The funnel plot for 'return of spontaneous circulation' was asymmetrical, possibly suggesting a publication bias (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). It is unlikely that smaller studies whose results favoured placebo would have significantly affected the pooled results of this analysis. All results discussed below are given as pooled RR and its 95% CI for aminophylline versus placebo.</P>
<SUBSECTION>
<HEADING LEVEL="3">Survival to discharge</HEADING>
<P>All studies (including 1254 participants) reported survival to hospital discharge&#65293;the primary outcome. These findings were homogeneous (Chi<SUP>2</SUP> = 0.08, degrees of freedom (df) = 1, P = 0.77). This event was rare, with only six survivors in total. We are reporting the analyses using a fixed-effect model. As seen in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, aminophylline was found to have no effect (RR 0.58, 95% CI 0.12 to 2.74). No change in the results was noted when a random-effects model was used. <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK> reported that their lone survivor was still alive at six months postevent. Four survivors in <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK> were still alive at one year, and one refused follow-up after discharge from the hospital.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Survival to admission</HEADING>
<P>Data on the secondary outcome&#65293;survival to hospital admission&#65293;were found to be homogeneous (Chi<SUP>2</SUP> = 2.73, df = 3, P = 0.43). Analysis showed that aminophylline had no effect on this secondary survival outcome (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>: RR 0.92, 95% CI 0.61 to 1.39).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Return of spontaneous circulation</HEADING>
<P>Data on return of spontaneous circulation were also found to be homogeneous (Chi<SUP>2</SUP> = 2.41, df = 4, P = 0.66). Analysis showed that aminophylline had no effect on return of spontaneous circulation (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>: RR 1.15, 95% CI 0.89 to 1.49).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Neurologic outcome</HEADING>
<P>Data about neurological outcomes were limited. <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK> reported that all five survivors had "excellent neurological and functional outcomes", and <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK> did not comment about the neurological status of the lone survivor in their study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>None of the trials reported adverse events (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Dirks-1999" TYPE="STUDY">Dirks 1999</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>). However, none of the data reporting schema that we reviewed specifically mentioned 'adverse events' as an outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>We performed a subgroup analysis on the basis of whether aminophylline was administered early in the resuscitation, using five minutes as the cut-off point. We used data from two studies in this analysis. <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK> provided raw study data, and we pulled relevant published data from <LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK> for an accumulated total of 37 participants. In this small sample of participants, no one survived to hospital discharge (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Three participants survived to admission (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>), and 11 had return of spontaneous circulation (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). We did not find benefit derived from the use of aminophylline in this subgroup analysis. Subgroup data from the other studies were not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>The results were unchanged (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) when we only selectively pooled data taken from studies with low risk of bias (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK>; <LINK REF="STD-Mader-2003" TYPE="STUDY">Mader 2003</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-09-29 14:17:04 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Summary of main results</HEADING>
<P>This systematic review did not find a survival benefit for the administration of IV aminophylline during adult, out-of-hospital bradyasystolic arrest. We did not find statistically significant heterogeneity between studies. Overall, the studies were well designed and the assessed risk of bias was low. Only <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK> was adequately powered to detect a significant difference in event rates for the primary outcome (return of spontaneous circulation). Because return of spontaneous circulation is a precursor to other survival outcomes, and our analysis demonstrated no significant benefit of aminophylline for this outcome, it is reasonable to conclude that a larger study is unlikely to demonstrate significant survival benefit. Nonetheless, no study was powered to detect a significant difference in our primary outcome&#65293;survival to hospital discharge. Given the relative rarity of survival to hospital admission (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and survival to hospital discharge (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), drawing conclusions about neurological status and adverse events is problematic as well.</P>
<P>Because the studies included in this review took place in the prehospital setting, the duration of arrest before administration of aminophylline was significant, with mean times from paramedic arrival to administration of study drug as long as 16 minutes (<LINK REF="STD-Mader-1997" TYPE="STUDY">Mader 1997</LINK>; <LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>). The subgroup analysis considered the effects of early administration of aminophylline but included only 37 participants with no survivors to hospital discharge (primary outcome). <LINK REF="STD-Mader-1999" TYPE="STUDY">Mader 1999</LINK> looked specifically at early administration, with mean times (from diagnosis of asystole to administration of study drug) less than five minutes. However, the mean time from dispatch to arrival to the scene in this population, where 49% of arrests were witnessed, was 6.5 minutes, suggesting that the duration of arrest before aminophylline exceeded ten minutes for most participants. This study accumulated 82 participants, none of whom survived. Hence, the effect of early administration of aminophylline remains unknown.</P>
<P>The unadjusted survival for adult out-of-hospital cardiac arrest in a large population-based registry was 4.9% (<LINK REF="REF-Hasegawa-2013" TYPE="REFERENCE">Hasegawa 2013</LINK>). Patients presenting in 'unshockable' rhythms such as asystole and pulseless electrical activity typically have a poorer prognosis (<LINK REF="REF-Thomas-2013" TYPE="REFERENCE">Thomas 2013</LINK>). The survival rate in this meta-analysis, which is derived primarily from a large Canadian study (<LINK REF="STD-Abu_x002d_Laban-2006" TYPE="STUDY">Abu-Laban 2006</LINK>), is in keeping with other published Canadian data (<LINK REF="REF-Steill-2004" TYPE="REFERENCE">Steill 2004</LINK>; <LINK REF="REF-Vaillancourt-2004" TYPE="REFERENCE">Vaillancourt 2004</LINK>). Survival from in-hospital adult asystolic arrest appears to be in the range of 10%, with good neurological outcomes reported in 61% of survivors (<LINK REF="REF-Morrison-2013" TYPE="REFERENCE">Morrison 2013</LINK>). The improved survival in this population may be attributable, in part, to the rapid onset of resuscitative efforts when a patient suffering a cardiac arrest is both monitored and witnessed (<LINK REF="REF-Brady-2011" TYPE="REFERENCE">Brady 2011</LINK>). Although 73% of in-hospital arrests are both monitored and witnessed, out-of-hospital arrests are witnessed by a health care provider in fewer than 9% of cases (<LINK REF="REF-Brady-2011" TYPE="REFERENCE">Brady 2011</LINK>; <LINK REF="REF-Hasegawa-2013" TYPE="REFERENCE">Hasegawa 2013</LINK>). Use of aminophylline has not been studied in the 'in-hospital' cardiac arrest population.</P>
<P>Because of our search strategy, we recovered a number of Chinese language studies, most of which were found through extensive searching in Google and Google Scholar. Some studies have noted the poor quality of reporting of randomised controlled trials in leading medical journals and conference proceedings in China (<LINK REF="REF-Xu-2008" TYPE="REFERENCE">Xu 2008</LINK>; <LINK REF="REF-Duan-2009" TYPE="REFERENCE">Duan 2009</LINK>; <LINK REF="REF-Chen-2010" TYPE="REFERENCE">Chen 2010</LINK>). One study found that only 6.8% of apparent randomised controlled trials in China were authentic randomised controlled trials (<LINK REF="REF-Wu-2009" TYPE="REFERENCE">Wu 2009</LINK>). We asked the lead author of that study to assess whether the 'apparent' randomised controlled trials that we identified were 'authentic' and found that nine of them were not prospectively designed (<LINK REF="STD-Meng-2001" TYPE="STUDY">Meng 2001</LINK>; <LINK REF="STD-Ma-2003" TYPE="STUDY">Ma 2003</LINK>; <LINK REF="STD-Dong-2006" TYPE="STUDY">Dong 2006</LINK>; <LINK REF="STD-Fu-2006" TYPE="STUDY">Fu 2006</LINK>; <LINK REF="STD-Jin-2006" TYPE="STUDY">Jin 2006</LINK>; <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK>; <LINK REF="STD-Xiao-2006" TYPE="STUDY">Xiao 2006</LINK>; <LINK REF="STD-Shi-2007" TYPE="STUDY">Shi 2007</LINK>; <LINK REF="STD-Guo-2008" TYPE="STUDY">Guo 2008</LINK>). None of the trials based in China met the criteria to be included in this review.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-07-27 13:25:07 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-07-27 13:22:27 +0100" MODIFIED_BY="[Empty name]">
<P>Although the mechanistic investigations and early case reports were promising, available data from well-designed randomised controlled trials do not warrant the addition of intravenous aminophylline to standard advanced cardiac life support algorithms for out-of-hospital bradyasystolic arrest at this time.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-07-27 13:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>Further research on administration of aminophylline in prehospital bradyasystolic arrest may not be justified. The low event rate for important outcomes such as survival to discharge dictates the need for larger trials to detect a difference. The data on use of aminophylline early in resuscitative efforts are not adequate to show whether it is effective. Future research directed towards a more carefully selected population of participants, in whom witnessed arrest occurs during prehospital care or in another health care setting where aminophylline can be administered quickly, may more aptly demonstrate its potential.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-09-29 09:51:24 +0100" MODIFIED_BY="[Empty name]">
<P>The review authors would like to thank Dr Taixiang Wu of the Chinese Cochrane Centre for assisting us in assessing the 'apparent' randomised controlled trials that we found.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-11-17 17:15:16 +0000" MODIFIED_BY="[Empty name]">
<P>KH: none known</P>
<P>KM: The author received a speaking fee from Fresenius Kabi for presenting at the European Society of Anaesthesia Symposium 2014 in Sweden on Propofol for Emergency Department Procedural Sedation and Analgesia.</P>
<P>RG: none known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-09-29 09:51:55 +0100" MODIFIED_BY="[Empty name]">
<P>Served as guarantor of the review: Dr Hurley<BR/>Drafted the protocol: Drs Hurley and Magee<BR/>Searched for trials: Dr Hurley<BR/>Obtained copies of trials: Dr Hurley<BR/>Selected which trials to include: Drs Hurley, Green and Magee<BR/>Extracted data from trials: Drs Hurley, Green and Magee<BR/>Entered data into RevMan: Drs Hurley and Magee<BR/>Carried out the analysis: Drs Hurley and Magee<BR/>Interpreted the analysis: Drs Hurley, Magee and Green<BR/>Drafted the final review: Drs Hurley, Green and Magee<BR/>Updated the review: Dr Hurley<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-11-28 03:15:42 +0000" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-07 01:47:42 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-09-29 10:38:14 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-09-29 10:07:05 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Abu_x002d_Laban-2006" MODIFIED="2015-09-29 10:05:10 +0100" MODIFIED_BY="[Empty name]" NAME="Abu-Laban 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-29 10:04:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Laban RB, McIntyre CM, Christenson JM, Van Beek CA, Innes GD, O'Brien R, et al</AU>
<TI>Aminophylline in bradyasystolic cardiac arrest: a randomized placebo-controlled trial</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>5</NO>
<PG>435</PG>
<IDENTIFIERS MODIFIED="2013-06-25 18:18:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-29 10:05:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Laban RB, McIntyre CM, Christenson JM, Van Beek CA, Innes GD, O'Brien RK, et al</AU>
<TI>Aminophylline in bradyasystolic cardiac arrest: a randomised placebo-controlled trial</TI>
<SO>The Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9522</NO>
<PG>1577-84</PG>
<IDENTIFIERS MODIFIED="2013-06-25 18:21:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-25 18:21:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16698410"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-06-25 18:14:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-25 18:14:51 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00312273"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dirks-1999" MODIFIED="2015-09-29 10:05:47 +0100" MODIFIED_BY="[Empty name]" NAME="Dirks 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-09-29 10:05:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dirks B, Lindner K</AU>
<TI>Randomized comparison using aminophylline vs. placebo patients in out-of-hospital cardiac arrest with asystole or pulseless electrical activity</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>18 Suppl I</NO>
<PG>I-314</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Mader-1997" MODIFIED="2013-07-27 14:06:19 +0100" MODIFIED_BY="[Empty name]" NAME="Mader 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-07-27 14:06:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mader TJ, Gibson P</AU>
<TI>Adenosine receptor antagonism in refractory asystolic cardiac arrest: results of a human pilot study</TI>
<SO>Resuscitation</SO>
<YR>1997</YR>
<VL>35</VL>
<NO>1</NO>
<PG>3-7</PG>
<IDENTIFIERS MODIFIED="2013-06-26 19:29:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-26 19:29:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9259053"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Mader-1999" MODIFIED="2013-06-26 19:29:11 +0100" MODIFIED_BY="[Empty name]" NAME="Mader 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-06-26 19:29:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mader TJ, Smithline HA, Gibson P</AU>
<TI>Aminophylline in undifferentiated out-of-hospital asystolic cardiac arrest</TI>
<SO>Resuscitation</SO>
<YR>1999</YR>
<VL>41</VL>
<NO>1</NO>
<PG>39-45</PG>
<IDENTIFIERS MODIFIED="2013-06-26 19:29:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-26 19:27:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10459591"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Mader-2003" MODIFIED="2015-09-29 10:07:05 +0100" MODIFIED_BY="[Empty name]" NAME="Mader 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-07-27 14:06:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mader TJ, Durkin LJ, Smithline HA, Stevens M</AU>
<TI>Aminophylline in atropine-resistant asystolic out-of-hospital cardiac arrest</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>5</NO>
<PG>357</PG>
<IDENTIFIERS MODIFIED="2013-06-26 19:29:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-29 10:07:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mader TJ, Smithline HA, Durkin L, Scriver G</AU>
<TI>A randomized controlled trial of intravenous aminophylline for atropine-resistant out-of-hospital asystolic cardiac arrest</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>3</NO>
<PG>192-7</PG>
<IDENTIFIERS MODIFIED="2013-06-26 19:29:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-26 19:29:03 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12615581"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-09-29 10:34:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Dong-2006" MODIFIED="2015-09-29 10:28:33 +0100" MODIFIED_BY="[Empty name]" NAME="Dong 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-29 10:28:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dong L, Jiang J</AU>
<TI>Clinical study of aminophylline on the treatment of cardiac arrest patient who are invalid with epinephrine</TI>
<SO>Practical Clinical Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>10</NO>
<PG>33-5. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-2006" MODIFIED="2015-09-29 10:28:49 +0100" MODIFIED_BY="[Empty name]" NAME="Fu 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-29 10:28:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu XH, Zhou GP, Zhu QY, Ma B, Chen C</AU>
<TI>A clinical survey for aminophylline and epinephrine for 30 patients with cardiac arrest</TI>
<SO>Jiangxi Medicine</SO>
<YR>2006</YR>
<VL>41</VL>
<NO>12</NO>
<PG>981-2. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2008" MODIFIED="2015-09-29 10:28:57 +0100" MODIFIED_BY="[Empty name]" NAME="Guo 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-09-29 10:28:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo XF</AU>
<TI>Effective observation on treatment of 30 cases with respiratory and cardiac arrest by aminophylline</TI>
<SO>Journal of Henan University of Science &amp; Technology: Medical Science</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>1</NO>
<PG>32-3. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jin-2006" MODIFIED="2015-09-29 10:29:05 +0100" MODIFIED_BY="[Empty name]" NAME="Jin 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-29 10:29:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin RH, Ma SZ, Li QL</AU>
<TI>Clinical research on joined application with aminophylline in early period of cardiac arrest</TI>
<SO>Lingnan Journal of Emergency Medicine</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>3</NO>
<PG>161-2. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2002" MODIFIED="2015-09-29 10:29:15 +0100" MODIFIED_BY="[Empty name]" NAME="Luo 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-09-29 10:29:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo ZC, Ling ZX, Wang PF</AU>
<TI>Study on administration of epinephrine combined with vasopressin and aminophylline during cardiopulmonary resuscitation</TI>
<SO>Modern Medical and Health</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>3</NO>
<PG>170-1. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2003" MODIFIED="2009-11-28 01:10:25 +0000" MODIFIED_BY="[Empty name]" NAME="Luo 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-28 01:10:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo JL, Wang CT, Pan J, An ZQ</AU>
<TI>Clinical application of ultra-routine dose epinephrine associated with aminophylline in the patients with cardiac arrest</TI>
<SO>Modern Medical and Health</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1529-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2003" MODIFIED="2015-09-29 10:29:24 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-09-29 10:29:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma Y, Meng QY, Qian YY, Zhizhong W, Tong G, Jinming L</AU>
<TI>Clinical effect of aminophylline associating with epinephrine on the treatment of cardiac arrest</TI>
<SO>Chinese Journal of Critical Care Medicine</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>4</NO>
<PG>232-3. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2006" MODIFIED="2015-09-29 10:29:37 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-29 10:29:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma SZ, Jin RH, Zhang YM</AU>
<TI>Patients with cardiac arrest early in conjunction with aminophylline and epinephrine effect</TI>
<SO>Practical Clinical Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>5</NO>
<PG>42-3. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meng-2001" MODIFIED="2009-11-28 01:03:34 +0000" MODIFIED_BY="[Empty name]" NAME="Meng 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-28 01:03:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meng QY, Lai H, Lai SH</AU>
<TI>Resuscitation using aminophylline in cardiac arrest refractory to epinephrine and atropine: results of a 32 patient study</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>11 Suppl C</NO>
<PG>210C</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2007" MODIFIED="2015-09-29 10:30:40 +0100" MODIFIED_BY="[Empty name]" NAME="Shi 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-09-29 10:30:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi QB, Huang X, Zhang FX, Wang SY, Wang GE, Sun GL</AU>
<TI>The application value study of the aminophylline and epinephrine with uniform method at the same time and rapidly combination on cardiopulmonary resuscitation</TI>
<SO>China Journal of Postgraduate Medicine</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>1</NO>
<PG>18-21. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2008" MODIFIED="2015-09-29 10:30:59 +0100" MODIFIED_BY="[Empty name]" NAME="Shi 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-09-29 10:30:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi QB, Zhang FX, Wang GE, Jiang FZ, Xu YS, Huang X</AU>
<TI>Study on the value of the formula of rapid synchronous stepwise increase in dosage of epinephrine combined with aminophylline (7 mg/kg) in cardiopulmonary resuscitation</TI>
<SO>Chinese Critical Care Medicine</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>7</NO>
<PG>409. Chinese</PG>
<IDENTIFIERS MODIFIED="2013-06-26 19:31:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-26 19:31:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18611339"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2009" MODIFIED="2015-09-29 10:32:37 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-09-29 10:32:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun Y</AU>
<TI>Clinical study on rapidly and synchronously using epinephrine in combination with aminophylline for patients undergoing cardiopulmonary resuscitation</TI>
<SO>Chinese Nursing Research</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>2</NO>
<PG>322-5. Chinese</PG>
<IDENTIFIERS MODIFIED="2013-06-26 19:34:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2002" MODIFIED="2015-09-29 10:33:03 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-09-29 10:33:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu B, Wang J, Hou Z</AU>
<TI>Study on administration of epinephrine combined with vasopressin and aminophylline during cardiopulmonary resuscitation</TI>
<SO>Modern Medicine Health</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>3</NO>
<PG>170-2. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2006" MODIFIED="2015-09-29 10:34:19 +0100" MODIFIED_BY="[Empty name]" NAME="Xiao 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-29 10:34:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao Z, Liu JM, Zhuang JY</AU>
<TI>The curative effect of epinephrine and aminophylline on cardiopulmonary resuscitation in patients with cardiac arrest onset out of hospital</TI>
<SO>Medicine World</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>148-50. Chinese</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-09-29 10:38:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Snell-2000" MODIFIED="2015-09-29 10:38:14 +0100" MODIFIED_BY="[Empty name]" NAME="Snell 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-09-29 10:38:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Snell CS, DuPont AM, Niezgoda JA, Cormier S</AU>
<TI>Aminophylline as an adjunctive therapy to advanced cardiac life support in pre-hospital cardiac arrest</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>5</NO>
<PG>509</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-07 01:47:42 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-07 01:47:42 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Belardinelli--1989" MODIFIED="2015-09-29 10:40:04 +0100" MODIFIED_BY="[Empty name]" NAME="Belardinelli  1989" TYPE="JOURNAL_ARTICLE">
<AU>Belardinelli L, Linder J, Berne R</AU>
<TI>The cardiac effects of adenosine</TI>
<SO>Progress in Cardiovascular Disease</SO>
<YR>1989</YR>
<VL>32</VL>
<NO>1</NO>
<PG>73&#8211;97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Belardinelli-1995" MODIFIED="2015-09-29 10:40:35 +0100" MODIFIED_BY="[Empty name]" NAME="Belardinelli 1995" TYPE="JOURNAL_ARTICLE">
<AU>Belardinelli L, Shryock JC, Song Y, Wang D, Srinivas M</AU>
<TI>Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes</TI>
<SO>FASEB Journal</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>5</NO>
<PG>359&#8211;65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brady-2011" MODIFIED="2013-07-27 14:09:24 +0100" MODIFIED_BY="[Empty name]" NAME="Brady 2011" TYPE="JOURNAL_ARTICLE">
<AU>Brady WJ, Gurka KK, Mehring B, Peberdy MA, O'Connor RE; American Heart Association's Get with the Guidelines (formerly, NRCPR) Investigators</AU>
<TI>In-hospital cardiac arrest: impact of monitoring and witnessed event on patient survival and neurologic status at hospital discharge</TI>
<SO>Resuscitation</SO>
<YR>2011</YR>
<VL>82</VL>
<NO>7</NO>
<PG>845-52</PG>
<IDENTIFIERS MODIFIED="2013-06-27 03:07:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-27 03:07:24 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.resuscitation.2011.02.028"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chen-2010" MODIFIED="2012-11-28 03:12:31 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2010" TYPE="JOURNAL_ARTICLE">
<AU>Chen Y, Li J, Ai C, Duan Y, Wang L, Zhang M, Hopewell S</AU>
<TI>Assessment of the quality of reporting in abstracts of randomized controlled trials published in five leading Chinese medical journals</TI>
<SO>PLoS One</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>8</NO>
<PG>e11926</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cummins-1991" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Cummins 1991" TYPE="JOURNAL_ARTICLE">
<AU>Cummins RO, Chamberlain DA, Abramson NS, Allen M, Baskett P, Becker L, et al</AU>
<TI>Recommended guidelines for uniform reporting of data from out-of-hospital cardiac arrest: the Utstein Style. Task Force of the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, and the Australian Resuscitation Council</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>8</NO>
<PG>861-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cummins-1997" MODIFIED="2013-07-27 14:10:27 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Cummins 1997" TYPE="JOURNAL_ARTICLE">
<AU>Cummins RO, Chamberlain D, Hazinski MF, Nadkarni V, Kloeck W, Kramer E, et al</AU>
<TI>Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital "Utstein style." American Heart Association.</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>5</NO>
<PG>650-79</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9140252"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dobson-1983" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Dobson 1983" TYPE="JOURNAL_ARTICLE">
<AU>Dobson J</AU>
<TI>Adenosine reduces catecholamine contractile responses in oxygenated and hypoxic atria</TI>
<SO>American Journal of Physiology</SO>
<YR>1983</YR>
<VL>245</VL>
<PG>H468&#8211;74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duan-2009" MODIFIED="2015-09-29 10:41:36 +0100" MODIFIED_BY="[Empty name]" NAME="Duan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Duan Y, Li J, Ai C, Chen Y, Chen P, Zhang M, Hopewell S</AU>
<TI>Quality of trials reported as conference abstracts in China: how well are they reported?</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>4</NO>
<PG>479-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hasegawa-2013" MODIFIED="2015-09-29 10:42:56 +0100" MODIFIED_BY="[Empty name]" NAME="Hasegawa 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hasegawa K, Tsugawa Y, Camargo CA Jr, Hiraide A, Brown DF</AU>
<TI>Regional variability in survival outcomes of out-of-hospital cardiac arrest: the All-Japan Utstein Registry</TI>
<SO>Resuscitation</SO>
<YR>2013</YR>
<VL>84</VL>
<NO>8</NO>
<PG>1099-107</PG>
<IDENTIFIERS MODIFIED="2013-06-27 02:54:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-27 02:54:40 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.resuscitation.2013.03.007"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herlitz-1994" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Herlitz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Herlitz J, Ekstrom L, Wennerblom B, Axelsson A, Bang A, Holmberg S</AU>
<TI>Predictors of early and late survival after out-of-hospital cardiac arrest in which asystole was the first recorded arrhythmia on scene</TI>
<SO>Resuscitation</SO>
<YR>1994</YR>
<VL>24</VL>
<PG>27-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deek JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-08-25 10:20:12 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]</SO>
<YR>2011</YR>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobs-2004" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Jacobs 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs I, Nadkarni V, Bahr J, Berg RA, Billi JE, Bossaert L, et al</AU>
<TI>Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries. A statement for healthcare professionals from a task force of the international liaison committee on resuscitation (American Heart Association, European Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa)</TI>
<SO>Resuscitation</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>3</NO>
<PG>233-49</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15582757"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kette-1998" MODIFIED="2013-07-27 14:14:13 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Kette 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kette F, Sbrojavacca R, Rellini G, Tosolini G, Capasso M, Arcidiacono D, et al</AU>
<TI>Epidemiology and survival rate of out-of-hospital cardiac arrest in north-east Italy: the F.A.C.S. study. Friuli Venezia Giulia Cardiac Arrest Cooperative Study</TI>
<SO>Resuscitation</SO>
<YR>1998</YR>
<VL>36</VL>
<NO>3</NO>
<PG>153-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2000" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Lee 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lee CC, Dill CE, Carter WA</AU>
<TI>Restoration of spontaneous circulation from asystole with aminophylline</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>3</NO>
<PG>350-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mader-2000" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Mader 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mader TJ, Bertolet B, Ornato JP, Gutterman JM</AU>
<TI>Aminophylline in the treatment of atropine-resistant bradyasystole</TI>
<SO>Resuscitation</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>2</NO>
<PG>105-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malcolm-1993" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Malcolm 1993" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm AD, Garratt CJ, Camm AJ</AU>
<TI>The therapeutic and diagnostic cardiac electrophysiological uses of adenosine</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>1993</YR>
<VL>7</VL>
<PG>139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morrison-2013" MODIFIED="2013-07-27 14:17:42 +0100" MODIFIED_BY="[Empty name]" NAME="Morrison 2013" TYPE="JOURNAL_ARTICLE">
<AU>Morrison LJ, Neumar RW, Zimmerman JL, Link MS, Newby LK, McMullan PW Jr, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease</AU>
<TI>Strategies for improving survival after in-hospital cardiac arrest in the United States: 2013 consensus recommendations. A consensus statement from the American Heart Association</TI>
<SO>Circulation</SO>
<YR>2013</YR>
<VL>127</VL>
<NO>14</NO>
<PG>1538-63</PG>
<IDENTIFIERS MODIFIED="2013-06-27 02:53:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-27 02:53:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1161/CIR.0b013e31828b2770"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neumar-2010" MODIFIED="2015-10-07 01:47:42 +0100" MODIFIED_BY="[Empty name]" NAME="Neumar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ</AU>
<TI>Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care</TI>
<SO>Circulation</SO>
<YR>2010</YR>
<VL>122</VL>
<NO>18 Suppl 3</NO>
<PG>S729-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perouansky-1998" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Perouansky 1998" TYPE="JOURNAL_ARTICLE">
<AU>Perouansky M, Shamir M, Hershkowitz E, Donchin Y</AU>
<TI>Successful resuscitation using aminophylline in refractory cardiac arrest with asystole</TI>
<SO>Resuscitation</SO>
<YR>1998</YR>
<VL>38</VL>
<NO>1</NO>
<PG>39-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-09-29 11:06:06 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudusky-2005" MODIFIED="2013-07-27 14:18:03 +0100" MODIFIED_BY="[Empty name]" NAME="Rudusky 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rudusky BM</AU>
<TI>Aminophylline: exploring cardiovascular benefits versus medical malcontent</TI>
<SO>Angiology</SO>
<YR>2005</YR>
<VL>56</VL>
<NO>3</NO>
<PG>295-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schrader-1977" MODIFIED="2015-09-29 10:45:10 +0100" MODIFIED_BY="[Empty name]" NAME="Schrader 1977" TYPE="JOURNAL_ARTICLE">
<AU>Schrader J, Baumann G, Gerlach E</AU>
<TI>Adenosine as an inhibitor of myocardial effects of catecholamines</TI>
<SO>Pflugers Archives - European Journal of Physiology</SO>
<YR>1977</YR>
<VL>372</VL>
<NO>1</NO>
<PG>29&#8211;35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sedgwick-1994" MODIFIED="2015-09-29 10:45:37 +0100" MODIFIED_BY="[Empty name]" NAME="Sedgwick 1994" TYPE="JOURNAL_ARTICLE">
<AU>Sedgwick ML, Dalziel K, Watson J, Carrington DJ, Cobbe SM</AU>
<TI>The causative rhythm in out-of-hospital cardiac arrests witnessed by the emergency medical services in the Heartstart Scotland Project</TI>
<SO>Resuscitation</SO>
<YR>1994</YR>
<VL>27</VL>
<NO>1</NO>
<PG>55&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steill-2004" MODIFIED="2013-07-27 14:16:53 +0100" MODIFIED_BY="[Empty name]" NAME="Steill 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stiell IG, Wells GA, Field B, Spaite DW, Nesbitt LP, De Maio VJ, et al; Ontario Prehospital Advanced Life Support Study Group</AU>
<TI>Advanced cardiac life support in out-of-hospital cardiac arrest</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>7</NO>
<PG>647-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2013" MODIFIED="2015-09-29 10:47:04 +0100" MODIFIED_BY="[Empty name]" NAME="Thomas 2013" TYPE="JOURNAL_ARTICLE">
<AU>Thomas AJ, Newgard CD, Fu R, Zive DM, Daya MR</AU>
<TI>Survival in out-of-hospital cardiac arrests with initial asystole or pulseless electrical activity and subsequent shockable rhythms</TI>
<SO>Resuscitation</SO>
<YR>2013</YR>
<VL>84</VL>
<NO>9</NO>
<PG>1261-6</PG>
<IDENTIFIERS MODIFIED="2013-06-27 02:53:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-27 02:53:56 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.resuscitation.2013.02.016"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vaillancourt-2004" MODIFIED="2013-06-24 18:31:23 +0100" MODIFIED_BY="[Empty name]" NAME="Vaillancourt 2004" TYPE="JOURNAL_ARTICLE">
<AU>Vaillancourt C, Stiell IG; Canadian Cardiovascular Outcomes Research Team</AU>
<TI>Cardiac arrest care and emergency medical services in Canada</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1081-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Visentin-1990" MODIFIED="2015-09-29 10:48:06 +0100" MODIFIED_BY="[Empty name]" NAME="Visentin 1990" TYPE="JOURNAL_ARTICLE">
<AU>Visentin S, Wu SN, Belardinelli L</AU>
<TI>Adenosine-induced changes in atrial action potential: contribution of Ca and K currents</TI>
<SO>American Journal of Physiology</SO>
<YR>1990</YR>
<VL>258</VL>
<NO>4 Pt 2</NO>
<PG>H1070-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Viskin-1993" MODIFIED="2008-09-08 13:38:09 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Viskin 1993" TYPE="JOURNAL_ARTICLE">
<AU>Viskin S, Belhassen B, Roth A, Reicher M, Averbuch M, Sheps D, et al</AU>
<TI>Aminophylline for bradyasystolic cardiac arrest refractory to atropine and epinephrine</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>118</VL>
<NO>4</NO>
<PG>279-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wesley-1989" MODIFIED="2015-09-29 10:48:53 +0100" MODIFIED_BY="[Empty name]" NAME="Wesley 1989" TYPE="JOURNAL_ARTICLE">
<AU>Wesley RJ, Belardinelli L</AU>
<TI>Role of endogenous adenosine in postdefibrillation bradyarrhythmia and hemodynamic depression</TI>
<SO>Circulation</SO>
<YR>1989</YR>
<VL>80</VL>
<NO>1</NO>
<PG>128-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2009" MODIFIED="2012-11-28 03:11:50 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wu T, Li Y, Bian Z, Liu G, Moher D</AU>
<TI>Randomized trials published in some Chinese journals: how many are randomized?</TI>
<SO>Trials</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-2008" MODIFIED="2015-09-29 10:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Xu L, Li J, Zhang M, Ai C, Wang L</AU>
<TI>Chinese authors do need CONSORT: reporting quality assessment for five leading Chinese medical journals</TI>
<SO>Contemporary Clinical Trials</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>5</NO>
<PG>727-31</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-09-29 14:21:14 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Hurley-2007" MODIFIED="2015-09-29 14:20:15 +0100" MODIFIED_BY="[Empty name]" NAME="Hurley 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Hurley K, Magee K, Green R</AU>
<TI>Aminophylline for bradyasystolic cardiac arrest in adults (Protocol)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-09-29 14:20:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-29 14:20:15 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006781"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hurley-2013" MODIFIED="2015-09-29 14:21:13 +0100" MODIFIED_BY="[Empty name]" NAME="Hurley 2013" TYPE="COCHRANE_REVIEW">
<AU>Hurley KF, Magee K, Green R</AU>
<TI>Aminophylline for bradyasystolic cardiac arrest in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2015-09-29 14:21:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-29 14:21:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006781.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-06-25 17:58:13 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-09-29 10:00:33 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-09-29 10:00:23 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-09-29 09:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abu_x002d_Laban-2006">
<CHAR_METHODS MODIFIED="2013-07-27 13:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Time frame: January 21, 2001 to September 3, 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-29 09:54:12 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: urban EMS system serving population of &gt; 2 million</P>
<P>Country: Canada</P>
<P>Cause of arrest: presumed (by the paramedic) cardiac in 799 (82.3%) and drug overdose in 80 (8.2%)</P>
<P>
<B>Control arm</B>&#65293;<B>485 participants</B>
</P>
<P>Mean age: 65.8 (SD: 17.6) years</P>
<P>Sex: 30.7% female</P>
<P>
<B>Intervention arm</B>&#65293;<B>486 participants</B>
</P>
<P>Mean age: 65.4 (SD: 17.4) years</P>
<P>Sex: 26.3% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-27 13:32:17 +0100" MODIFIED_BY="[Empty name]">
<P>Aminophylline 250 mg IV followed by 10 mL normal saline flush. If the participant remained pulseless and in bradyasystole after 90 seconds, a second dose of aminophylline could be administered.</P>
<P>Timing: Endotracheal intubation, ventilation with 100% oxygen and appropriate initial ACLS pharmacotherapy (atropine 3 mg and epinephrine 1 mg) had to be carried out without improvement in cardiac rhythm before aminophylline or placebo was administered</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 09:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: return of spontaneous circulation</P>
<P>Other outcomes considered in this review.</P>
<UL>
<LI>Survival to hospital admission.</LI>
<LI>Survival to hospital discharge.</LI>
<LI>Neurological outcomes: Glasgow Coma Scale, Glasgow-Pittsburgh Cerebral and Overall Performance Scales, Modified Mini-Mental State Exam, Functional Status Questionnaire.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-27 13:33:52 +0100" MODIFIED_BY="[Empty name]">
<P>Data collected according to Utstein style</P>
<P>Mean time from arrival of paramedic crew to administration of aminophylline: 14.5 minutes</P>
<P>Mean time from arrival of paramedic crew to administration of placebo: 14.8 minutes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-27 14:22:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dirks-1999">
<CHAR_METHODS MODIFIED="2012-07-24 17:31:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Time frame: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-27 13:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: urban EMS system serving population of 188,800</P>
<P>Country: Germany</P>
<P>Cause of arrest: cardiac in 19 (61.3%) participants in the aminophylline group and in 24 (64.9%) participants in the control group</P>
<P>
<B>Control arm</B>&#65293;<B>37 participants</B>
</P>
<P>Mean age: not reported</P>
<P>Sex: not reported</P>
<P>
<B>Intervention arm</B>&#65293;<B>31 participants</B>
</P>
<P>Mean age: not reported</P>
<P>Sex: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-27 14:22:55 +0100" MODIFIED_BY="[Empty name]">
<P>Aminophylline 240 mg IV</P>
<P>Timing: Cardiopulmonary resuscitation (CPR) and appropriate initial ACLS pharmacotherapy (epinephrine 1 mg) had to be carried out without improvement in cardiac rhythm before administration of aminophylline or placebo. Endotracheal intubation, atropine 3 mg and repeated doses of epinephrine were carried out afterwards, if needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-27 13:39:44 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: return of spontaneous circulation</P>
<P>Other outcomes considered in this review.</P>
<UL>
<LI>Survival to hospital admission.</LI>
<LI>Survival to hospital discharge.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-27 13:39:50 +0100" MODIFIED_BY="[Empty name]">
<P>Data collected according to Utstein style</P>
<P>Median time from arrival of paramedic crew to administration of aminophylline: 11 minutes</P>
<P>Median time from arrival of paramedic crew to administration of placebo: 15 minutes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-27 13:42:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mader-1997">
<CHAR_METHODS MODIFIED="2009-11-30 16:58:21 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Time frame: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-27 13:41:36 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: moderate-sized urban EMS system</P>
<P>Country: USA</P>
<P>Cause of arrest: not specified</P>
<P>
<B>Control arm</B>&#65293;<B>8 participants</B>
</P>
<P>Mean age: 67.5 years</P>
<P>Median age: 72.5 years</P>
<P>Sex: 25% female</P>
<P>
<B>Intervention arm</B>&#65293;<B>14 participants</B>
</P>
<P>Mean age: 76.8 years</P>
<P>Median age: 78.5 years</P>
<P>Sex: 42.8% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-27 13:41:54 +0100" MODIFIED_BY="[Empty name]">
<P>Aminophylline 250 mg IV</P>
<P>Timing: appropriate initial ACLS pharmacotherapy (atropine 1 mg and epinephrine 1 mg) had to be carried out without improvement in cardiac rhythm for at least 1 minute before administration of aminophylline or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-27 13:41:57 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: return of spontaneous circulation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-27 13:42:02 +0100" MODIFIED_BY="[Empty name]">
<P>The authors did not specify data collection according to Utstein style</P>
<P>Mean time from arrival of paramedic crew to administration of aminophylline: 16.6 minutes</P>
<P>Mean time from arrival of paramedic crew to administration of placebo: 13.1 minutes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-27 13:46:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mader-1999">
<CHAR_METHODS MODIFIED="2013-07-27 13:43:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Time frame: June 1996 to August 1997</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-27 13:45:55 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: urban EMS system</P>
<P>Country: USA</P>
<P>
<B>Control arm</B>&#65293;<B>45 participants</B>
</P>
<P>Mean age: 70 years (95% CI 65 to 75)</P>
<P>Sex: 36% female</P>
<P>Cause of arrest: primary ischaemic cardiac event suspected in 35 (77.8%)</P>
<P>
<B>Intervention arm</B>&#65293;<B>37 participants</B>
</P>
<P>Mean age: 66 years (95% CI 61 to 71)</P>
<P>Sex: 51% female</P>
<P>Cause of arrest: primary ischaemic cardiac event suspected in 31 (83.8%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-27 13:46:02 +0100" MODIFIED_BY="[Empty name]">
<P>Aminophylline 250 mg IV</P>
<P>Timing: Aminophylline or placebo was administered along with appropriate initial ACLS pharmacotherapy (atropine and epinephrine)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-27 13:46:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: return of spontaneous circulation</P>
<P>Other outcomes considered in this review.</P>
<UL>
<LI>Survival to hospital admission</LI>
<LI>Survival to hospital discharge</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-27 13:46:44 +0100" MODIFIED_BY="[Empty name]">
<P>The authors did not specify data collection according to Utstein style, although the 1991 guidelines are cited in the discussion</P>
<P>Mean time from diagnosis of asystole to administration of aminophylline: 4.9 minutes</P>
<P>Mean time from diagnosis of asystole to administration of placebo: 4.6 minutes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 09:59:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mader-2003">
<CHAR_METHODS MODIFIED="2013-07-27 13:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Time frame: February 1999 to August 2000</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-29 09:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: urban EMS system serving population of 250,000</P>
<P>Country: USA</P>
<P>Cause of arrest: 'uncertain' in most cases</P>
<P>
<B>Control arm</B>&#65293;<B>45 participants</B>
</P>
<P>Mean age: 67 years (95% CI 62 to 72)</P>
<P>Sex: 36% female</P>
<P>
<B>Intervention arm</B>&#65293;<B>66 participants</B>
</P>
<P>Mean age: 65 years (95% CI 61 to 68)</P>
<P>Sex: 51% female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-27 13:50:32 +0100" MODIFIED_BY="[Empty name]">
<P>Aminophylline 250 mg IV</P>
<P>Timing: Appropriate initial ACLS pharmacotherapy (atropine and epinephrine) had to be carried out without improvement in cardiac rhythm for at least 2 minutes before aminophylline or placebo was administered</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-27 13:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: return of spontaneous circulation</P>
<P>Other outcomes considered in this review.</P>
<UL>
<LI>Survival to hospital admission.</LI>
<LI>Survival to hospital discharge.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-27 13:51:03 +0100" MODIFIED_BY="[Empty name]">
<P>Data on return of spontaneous circulation collected according to Utstein style</P>
<P>Mean time from diagnosis of asystole to administration of aminophylline: 7.2 minutes</P>
<P>Mean time from diagnosis of asystole to administration of placebo: 6.7 minutes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-09-29 09:59:44 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:00:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dong-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:00:37 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:00:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:00:49 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:00:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:00:51 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:00:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:00:55 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-28 01:48:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-28 01:48:35 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed comparison of epinephrine (control) with epinephrine, vasopressin and aminophylline (intervention)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-28 01:38:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-28 01:38:54 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed comparison of epinephrine (control) with higher doses of epinephrine combined with aminophylline (intervention)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:01:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:01:03 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:01:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:01:12 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:01:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meng-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:01:18 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:01:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:01:21 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-27 13:53:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-27 13:53:19 +0100" MODIFIED_BY="[Empty name]">
<P>Mixed comparison using escalating doses of epinephrine combined with aminophylline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-29 09:59:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-29 09:59:44 +0100" MODIFIED_BY="[Empty name]">
<P>Study population unclear (not specified beyond 'cardiac arrest'. Mixed comparison of standard dose epinephrine, high dose epinephrine and standard dose epinephrine in conjunction with simultaneous administration of aminophylline. No placebo apparent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-28 01:48:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-28 01:48:41 +0000" MODIFIED_BY="[Empty name]">
<P>Mixed comparison of epinephrine (control) with epinephrine, vasopressin and aminophylline (intervention)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-30 14:01:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiao-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-30 14:01:28 +0000" MODIFIED_BY="[Empty name]">
<P>No prospective design of protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-09-29 10:00:33 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-09-29 10:00:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Snell-2000">
<CHAR_METHODS MODIFIED="2012-07-24 19:02:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Time frame: 18 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-27 13:55:34 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: prehospital, community setting</P>
<P>Country: USA</P>
<P>Cause of arrest: not reported</P>
<P>
<B>Control arm</B>&#65293;<B>36 participants</B>
</P>
<P>Mean age: not reported</P>
<P>Sex: not reported</P>
<P>
<B>Intervention arm</B>&#65293;<B>36 participants</B>
</P>
<P>Mean age: not reported</P>
<P>Sex: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-27 13:55:38 +0100" MODIFIED_BY="[Empty name]">
<P>Aminophylline 250 mg IV</P>
<P>Timing: administered in addition to standard ACLS therapy, after the initial dose of epinephrine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-27 13:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: return of spontaneous circulation and survival to ICU admission</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 10:00:33 +0100" MODIFIED_BY="[Empty name]">
<P>Published in abstract form only (conference proceedings)</P>
<P>"Eligible patients included adults in non-traumatic cardiopulmonary arrest with an arrhythmia requiring epinephrine by ACLS protocol."</P>
<P>The authors do not specify the types of cardiac rhythms that were considered eligible for study enrolment. All pulseless rhythms may be treated with epinephrine. We suspect that a subset of the participants in this study would fit our population of interest (those with bradyasystole). We were not able to get more information or study data from the authors.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-09-29 10:00:23 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-09-29 10:00:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-27 13:34:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Laban-2006">
<DESCRIPTION>
<P>"Randomisation was done by computer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-27 13:40:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dirks-1999">
<DESCRIPTION>
<P>Not reported in the abstract/poster</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-27 13:42:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1997">
<DESCRIPTION>
<P>"Randomization was provided by the investigational drug service"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-27 13:46:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1999">
<DESCRIPTION>
<P>Block randomisation was provided by the Baystate Medical Center investigational drug service</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-29 10:00:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-2003">
<DESCRIPTION>
<P>Randomisation was provided by the Baystate Medical Center investigational drug service. "A single allocation sequence was constructed using a permuted block design with a blocking factor of four."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-09-29 10:00:22 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-27 13:34:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Laban-2006">
<DESCRIPTION>
<P>Study drug kits were prepared by a third party (Abbott Laboratories) and were distributed to "each ambulance station in batches of eight, and carried on ambulances in batches of two"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-27 13:40:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dirks-1999">
<DESCRIPTION>
<P>Not reported in the abstract/poster</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-27 13:42:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1997">
<DESCRIPTION>
<P>"Drug randomization for a given patient was determined by the contents of the syringe assigned to the code bag in the ambulance<BR/>responding to the call"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-27 13:47:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1999">
<DESCRIPTION>
<P>"Aminophylline and placebo were kept in serially numbered identical prefilled single dose syringes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-29 10:00:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-2003">
<DESCRIPTION>
<P>A third party prepared "identically appearing pre-filled syringes of aminophylline and placebo and sequentially numbered them according to the allocation sequence. Each ambulance was stocked with the study syringe, which was replaced with the next sequentially numbered syringe after it was used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-07-27 13:52:02 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-27 13:34:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Laban-2006">
<DESCRIPTION>
<P>"Study personnel and investigators, caregivers, patients, and their families remained blinded throughout the study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-27 13:40:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dirks-1999">
<DESCRIPTION>
<P>Described as "double-blind" but the means of blinding are not reported in the abstract/poster</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-27 13:42:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1997">
<DESCRIPTION>
<P>Investigators, caregivers, participants and their families remained blinded throughout the study period. Participants who did not meet inclusion criteria were prospectively excluded from the study (before unblinding)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-27 13:47:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1999">
<DESCRIPTION>
<P>Investigators, caregivers, participants and their families remained blinded throughout the study period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-27 13:52:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-2003">
<DESCRIPTION>
<P>Investigators, caregivers, participants and their families remained blinded throughout the study period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-07-27 13:52:08 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-27 13:34:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Laban-2006">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-27 13:40:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dirks-1999">
<DESCRIPTION>
<P>Not reported in the abstract/poster</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-27 13:43:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1997">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-27 13:48:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1999">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-27 13:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-2003">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-09-29 09:59:24 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-29 09:56:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Laban-2006">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-29 09:57:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dirks-1999">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-29 09:58:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1997">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-29 09:58:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1999">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-29 09:59:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-2003">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-09-29 11:32:34 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-09-29 11:32:34 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-10-03 15:55:57 +0100" MODIFIED_BY="Grade Profiler">Aminophylline compared to placebo for bradyasystolic cardiac arrest in adults</TITLE>
<TABLE COLS="7" ROWS="28">
<TR>
<TD COLSPAN="7">
<P>
<B>Aminophylline compared to placebo for bradyasystolic cardiac arrest in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: participants with bradyasystolic cardiac arrest in adults<BR/>
<B>Settings</B>: prehospital<BR/>
<B>Intervention</B>: aminophylline<BR/>
<B>Comparison</B>: placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Aminophylline</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Survival to hospital discharge</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.58 </B>
<BR/>(0.12 to 2.74)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1254<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
<BR/>(1 to 17)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Return of spontaneous circulation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 1.15 </B>
<BR/>(0.89 to 1.49)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1254<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>234 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>260 per 1000</B>
<BR/>(214 to 313)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>223 per 1000</B>
<BR/>(182 to 271)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Survival to admission</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.92 </B>
<BR/>(0.61 to 1.39)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1232<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>80 per 1000</B>
<BR/>(55 to 116)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>93 per 1000</B>
<BR/>(63 to 134)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Early administration of aminophylline: survival to hospital discharge</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>37<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Early administration of aminophylline: survival to hospital admission</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.22 </B>
<BR/>(0.02 to 2.36)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>37<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>37 per 1000</B>
<BR/>(4 to 294)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>226 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>60 per 1000</B>
<BR/>(6 to 408)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Early administration of aminophylline: return of spontaneous circulation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 1.61 </B>
<BR/>(0.38 to 6.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>37<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>349 per 1000</B>
<BR/>(112 to 693)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>284 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>390 per 1000</B>
<BR/>(131 to 729)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Dirks 1999 has unclear risk of bias because of limited information about the methodology on which to base the assessment. However, this represents a small number of participants.<BR/>
<SUP>b</SUP>Because of the nature of the event (survival to hospital discharge from cardiac arrest), the 'event' is relatively rare (i.e. fewer than 300 events).<BR/>
<SUP>c</SUP>The nature of the outcome required data on the time at which the drug was administered. The subgroup was small and data were available from only 2 of the 5 included studies.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-06-26 18:56:23 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-06-26 18:56:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Aminophylline vs. placebo</NAME>
<DICH_OUTCOME CHI2="0.08257120745184296" CI_END="2.7412461353327844" CI_START="0.12168539821998918" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5775548697716747" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.4379480324083958" LOG_CI_START="-0.9147615323118052" LOG_EFFECT_SIZE="-0.23840674995170477" METHOD="MH" MODIFIED="2012-10-29 16:22:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7738427739711983" P_Q="1.0" P_Z="0.48965150569179183" Q="0.0" RANDOM="NO" SCALE="161.5" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="634" TOTAL_2="620" WEIGHT="99.99999999999999" Z="0.6908632211427278">
<NAME>Survival to hospital discharge</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9909446468540493" CI_START="0.1104447638100182" EFFECT_SIZE="0.6639118457300276" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6010757042980417" LOG_CI_START="-0.9568548692205299" LOG_EFFECT_SIZE="-0.17788958246124412" MODIFIED="2012-07-24 20:22:22 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.9151361307655235" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="486" TOTAL_2="485" VAR="0.8374741378324932" WEIGHT="68.89924908359727"/>
<DICH_DATA CI_END="9.821936300011856" CI_START="0.015188853690343881" EFFECT_SIZE="0.3862433862433862" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9921971131958033" LOG_CI_START="-1.81847500130138" LOG_EFFECT_SIZE="-0.4131389440527883" MODIFIED="2012-10-03 15:03:26 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.6510027131069989" STUDY_ID="STD-Dirks-1999" TOTAL_1="31" TOTAL_2="37" VAR="2.725809958686671" WEIGHT="31.10075091640272"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-24 20:18:49 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.0" STUDY_ID="STD-Mader-1997" TOTAL_1="14" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-24 20:16:26 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.0" STUDY_ID="STD-Mader-1999" TOTAL_1="37" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-24 20:20:53 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.0" STUDY_ID="STD-Mader-2003" TOTAL_1="66" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4102687284928375" CI_END="1.4928719579240397" CI_START="0.8888447541289473" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1519250880100638" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="145" I2="0.0" I2_Q="100.0" ID="CMP-001.02" LOG_CI_END="0.17402256033608263" LOG_CI_START="-0.05117408640076879" LOG_EFFECT_SIZE="0.06142423696765691" METHOD="MH" MODIFIED="2009-12-03 14:57:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.660772401599393" P_Q="0.0" P_Z="0.2849829160819747" Q="4.4025209783858957E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="634" TOTAL_2="620" WEIGHT="100.00000000000001" Z="1.0691925832726952">
<NAME>Return of spontaneous circulation</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.400039256612684" CI_START="0.7773728136796714" EFFECT_SIZE="1.0432413221182324" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="115" LOG_CI_END="0.14614021331483917" LOG_CI_START="-0.1093706516071897" LOG_EFFECT_SIZE="0.018384780853824716" MODIFIED="2009-12-03 14:56:19 +0000" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.15008834685437952" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="486" TOTAL_2="485" VAR="0.02252651186148054" WEIGHT="81.54232154650441"/>
<DICH_DATA CI_END="4.041669594046843" CI_START="0.5719172559109852" EFFECT_SIZE="1.5203619909502262" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.6065608071141266" LOG_CI_START="-0.24266679970465993" LOG_EFFECT_SIZE="0.18194700370473332" MODIFIED="2009-12-03 14:56:21 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.49884049998980606" STUDY_ID="STD-Dirks-1999" TOTAL_1="31" TOTAL_2="37" VAR="0.2488418444300797" WEIGHT="6.097078100234126"/>
<DICH_DATA CI_END="41.324681389199085" CI_START="0.36596668822899225" EFFECT_SIZE="3.888888888888889" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.616209513872133" LOG_CI_START="-0.43655844405023136" LOG_EFFECT_SIZE="0.5898255349109508" MODIFIED="2009-12-03 14:56:25 +0000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="1.205806059848869" STUDY_ID="STD-Mader-1997" TOTAL_1="14" TOTAL_2="8" VAR="1.453968253968254" WEIGHT="0.7674643762532466"/>
<DICH_DATA CI_END="4.14782974660436" CI_START="0.529141144659888" EFFECT_SIZE="1.4814814814814814" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.617820921866541" LOG_CI_START="-0.27642846752859096" LOG_EFFECT_SIZE="0.17069622716897506" MODIFIED="2009-12-03 14:56:28 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.5252865179365694" STUDY_ID="STD-Mader-1999" TOTAL_1="37" TOTAL_2="45" VAR="0.2759259259259259" WEIGHT="5.559437067005225"/>
<DICH_DATA CI_END="4.299513280332315" CI_START="0.5929171117524863" EFFECT_SIZE="1.596638655462185" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6334192947354214" LOG_CI_START="-0.22700601561482492" LOG_EFFECT_SIZE="0.20320663956029822" MODIFIED="2009-12-03 14:56:29 +0000" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.505418086473712" STUDY_ID="STD-Mader-2003" TOTAL_1="66" TOTAL_2="45" VAR="0.2554474421347486" WEIGHT="6.033698910003002"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.859077919168882" CI_END="1.372694027561876" CI_START="0.6107120868424054" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9155986206676043" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.1375737441194537" LOG_CI_START="-0.21416348462667412" LOG_EFFECT_SIZE="-0.038294870253610225" METHOD="MH" MODIFIED="2013-06-26 18:53:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5816785062990257" P_Q="1.0" P_Z="0.6695422301722445" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="634" TOTAL_2="620" WEIGHT="100.00000000000001" Z="0.42677635664141544">
<NAME>Survival to admission</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3942192906180906" CI_START="0.5224079090751304" EFFECT_SIZE="0.853434932730087" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="37" LOG_CI_END="0.14433108740280554" LOG_CI_START="-0.2819902566149033" LOG_EFFECT_SIZE="-0.0688295846060489" MODIFIED="2009-12-03 14:58:29 +0000" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.2504232678006899" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="486" TOTAL_2="485" VAR="0.06271181305597606" WEIGHT="70.6003384154771"/>
<DICH_DATA CI_END="6.225495041543298" CI_START="0.669012062629708" EFFECT_SIZE="2.0408163265306123" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.7941738915528914" LOG_CI_START="-0.17456605160991884" LOG_EFFECT_SIZE="0.3098039199714864" MODIFIED="2009-12-03 14:58:34 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.5690426379538917" STUDY_ID="STD-Dirks-1999" TOTAL_1="31" TOTAL_2="37" VAR="0.32380952380952377" WEIGHT="8.822199162724164"/>
<DICH_DATA CI_END="9.985128135691944" CI_START="0.029037266669214835" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9993536423931896" LOG_CI_START="-1.5370442669783493" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2013-06-26 18:53:54 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="1.4898926873369838" STUDY_ID="STD-Mader-1997" TOTAL_1="14" TOTAL_2="8" VAR="2.2197802197802194" WEIGHT="2.4115102225875575"/>
<DICH_DATA CI_END="4.323164166348316" CI_START="0.18920415895964512" EFFECT_SIZE="0.9044117647058824" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.6358017275959871" LOG_CI_START="-0.7230693214576261" LOG_EFFECT_SIZE="-0.04363379693081958" MODIFIED="2009-12-03 14:58:35 +0000" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.7982075807342691" STUDY_ID="STD-Mader-1999" TOTAL_1="37" TOTAL_2="45" VAR="0.6371353419416548" WEIGHT="6.76851649716883"/>
<DICH_DATA CI_END="2.038381302266181" CI_START="0.13068662749382887" EFFECT_SIZE="0.5161290322580645" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.30928542696223016" LOG_CI_START="-0.883768849318926" LOG_EFFECT_SIZE="-0.2872417111783479" MODIFIED="2009-12-03 14:58:36 +0000" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.7008059876014648" STUDY_ID="STD-Mader-2003" TOTAL_1="66" TOTAL_2="45" VAR="0.49112903225806454" WEIGHT="11.39743570204237"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-07-24 20:13:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Early administration of aminophylline: Survival to hospital discharge</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-24 20:09:34 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.0" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="14" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-24 20:09:45 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.0" STUDY_ID="STD-Mader-1997" TOTAL_1="3" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0019846782015045354" CI_END="2.3586194171302513" CI_START="0.021061601684572023" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.22288181327576903" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.37265786951019064" LOG_CI_START="-1.6765086048351836" LOG_EFFECT_SIZE="-0.6519253676624965" METHOD="MH" MODIFIED="2012-07-24 20:13:09 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9644662239792842" P_Q="1.0" P_Z="0.21236354575567729" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0" Z="1.2470926664313262">
<NAME>Early administration of aminophylline: Survival to hospital admission</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.839983747283568" CI_START="0.009443728216587182" EFFECT_SIZE="0.21379310344827587" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6848439032814138" LOG_CI_START="-2.024856520082818" LOG_EFFECT_SIZE="-0.6700063084007022" MODIFIED="2012-07-24 20:10:58 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="1.5916914419175714" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="14" TOTAL_2="17" VAR="2.5334816462736374" WEIGHT="62.601187263896385"/>
<DICH_DATA CI_END="8.615071458414736" CI_START="0.006580252140364669" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9352588840900831" LOG_CI_START="-2.1817574648858837" LOG_EFFECT_SIZE="-0.6232492903979004" MODIFIED="2012-07-24 20:11:10 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="1.8309508328682538" STUDY_ID="STD-Mader-1997" TOTAL_1="3" TOTAL_2="3" VAR="3.352380952380952" WEIGHT="37.398812736103615"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.34362381903931016" CI_END="6.772268986044811" CI_START="0.3822083734466576" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6088560885608856" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.8307341994125302" LOG_CI_START="-0.41769980262416967" LOG_EFFECT_SIZE="0.20651719839418028" METHOD="MH" MODIFIED="2012-07-24 20:14:48 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5577451027753488" P_Q="1.0" P_Z="0.5167014469830902" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="20" WEIGHT="100.0" Z="0.6484383962313894">
<NAME>Early administration of aminophylline: Return of spontaneous circulation</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.5203705098866065" CI_START="0.2591877252124727" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.8142722745398061" LOG_CI_START="-0.5863855699261324" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2012-07-24 20:14:33 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.8227533512074423" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="14" TOTAL_2="17" VAR="0.676923076923077" WEIGHT="88.56088560885608"/>
<DICH_DATA CI_END="119.22966168897543" CI_START="0.13419479493062617" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="2.076384311657128" LOG_CI_START="-0.8722643290012035" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2012-07-24 20:14:48 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="1.7320508075688772" STUDY_ID="STD-Mader-1997" TOTAL_1="3" TOTAL_2="3" VAR="3.0" WEIGHT="11.43911439114391"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9909446468540493" CI_START="0.1104447638100182" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6639118457300276" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.6010757042980417" LOG_CI_START="-0.9568548692205299" LOG_EFFECT_SIZE="-0.17788958246124412" METHOD="MH" MODIFIED="2013-06-26 18:50:53 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6544490281752393" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="603" TOTAL_2="583" WEIGHT="100.0" Z="0.4475901311333375">
<NAME>Sensitivity analysis: survival to discharge</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9909446468540493" CI_START="0.1104447638100182" EFFECT_SIZE="0.6639118457300276" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6010757042980417" LOG_CI_START="-0.9568548692205299" LOG_EFFECT_SIZE="-0.17788958246124412" MODIFIED="2013-06-26 18:49:41 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.9151361307655235" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="486" TOTAL_2="485" VAR="0.8374741378324932" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-26 18:50:40 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.0" STUDY_ID="STD-Mader-1997" TOTAL_1="14" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-26 18:50:43 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.0" STUDY_ID="STD-Mader-1999" TOTAL_1="37" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-26 18:50:53 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.0" STUDY_ID="STD-Mader-2003" TOTAL_1="66" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5508059297863295" CI_END="1.2501951184196745" CI_START="0.5205623939846084" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8067245898027509" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="47" I2="0.0" I2_Q="100.0" ID="CMP-001.08" LOG_CI_END="0.09697779880007723" LOG_CI_START="-0.2835272090175647" LOG_EFFECT_SIZE="-0.09327470510874372" METHOD="MH" MODIFIED="2013-06-26 18:55:01 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9075959059633305" P_Q="0.0" P_Z="0.3365986787893185" Q="1.5420715298113742E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="603" TOTAL_2="583" WEIGHT="100.0" Z="0.9609075251348413">
<NAME>Sensitivity analysis: survival to admission</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3942192906180906" CI_START="0.5224079090751304" EFFECT_SIZE="0.853434932730087" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="37" LOG_CI_END="0.14433108740280554" LOG_CI_START="-0.2819902566149033" LOG_EFFECT_SIZE="-0.0688295846060489" MODIFIED="2013-06-26 18:54:13 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.2504232678006899" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="486" TOTAL_2="485" VAR="0.06271181305597606" WEIGHT="77.4314995176039"/>
<DICH_DATA CI_END="9.985128135691944" CI_START="0.029037266669214835" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9993536423931896" LOG_CI_START="-1.5370442669783493" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2013-06-26 18:54:36 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="1.4898926873369838" STUDY_ID="STD-Mader-1997" TOTAL_1="14" TOTAL_2="8" VAR="2.2197802197802194" WEIGHT="2.644843591798575"/>
<DICH_DATA CI_END="4.323164166348316" CI_START="0.18920415895964512" EFFECT_SIZE="0.9044117647058824" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.6358017275959871" LOG_CI_START="-0.7230693214576261" LOG_EFFECT_SIZE="-0.04363379693081958" MODIFIED="2013-06-26 18:54:48 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.7982075807342691" STUDY_ID="STD-Mader-1999" TOTAL_1="37" TOTAL_2="45" VAR="0.6371353419416548" WEIGHT="7.423425916192622"/>
<DICH_DATA CI_END="2.038381302266181" CI_START="0.13068662749382887" EFFECT_SIZE="0.5161290322580645" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.30928542696223016" LOG_CI_START="-0.883768849318926" LOG_EFFECT_SIZE="-0.2872417111783479" MODIFIED="2013-06-26 18:55:01 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.7008059876014648" STUDY_ID="STD-Mader-2003" TOTAL_1="66" TOTAL_2="45" VAR="0.49112903225806454" WEIGHT="12.500230974404907"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.066339715242055" CI_END="1.4761003617934616" CI_START="0.861994190529654" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.128002631426312" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="132" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.16911588668167696" LOG_CI_START="-0.06449566112356571" LOG_EFFECT_SIZE="0.05231011277905565" METHOD="MH" MODIFIED="2013-06-26 18:56:23 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5587524714174991" P_Q="1.0" P_Z="0.38008095127466557" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="603" TOTAL_2="583" WEIGHT="99.99999999999999" Z="0.8777471665026708">
<NAME>Sensitivity analysis: return of spontaneous circulation</NAME>
<GROUP_LABEL_1>Aminophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours aminophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.400039256612684" CI_START="0.7773728136796714" EFFECT_SIZE="1.0432413221182324" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="115" LOG_CI_END="0.14614021331483917" LOG_CI_START="-0.1093706516071897" LOG_EFFECT_SIZE="0.018384780853824716" MODIFIED="2013-06-26 18:56:15 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.15008834685437952" STUDY_ID="STD-Abu_x002d_Laban-2006" TOTAL_1="486" TOTAL_2="485" VAR="0.02252651186148054" WEIGHT="86.83683094924835"/>
<DICH_DATA CI_END="41.324681389199085" CI_START="0.36596668822899225" EFFECT_SIZE="3.888888888888889" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.616209513872133" LOG_CI_START="-0.43655844405023136" LOG_EFFECT_SIZE="0.5898255349109508" MODIFIED="2013-06-26 18:56:23 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="1.205806059848869" STUDY_ID="STD-Mader-1997" TOTAL_1="14" TOTAL_2="8" VAR="1.453968253968254" WEIGHT="0.8172955225743194"/>
<DICH_DATA CI_END="4.14782974660436" CI_START="0.529141144659888" EFFECT_SIZE="1.4814814814814814" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.617820921866541" LOG_CI_START="-0.27642846752859096" LOG_EFFECT_SIZE="0.17069622716897506" MODIFIED="2013-06-26 18:56:23 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.5252865179365694" STUDY_ID="STD-Mader-1999" TOTAL_1="37" TOTAL_2="45" VAR="0.2759259259259259" WEIGHT="5.920409029379826"/>
<DICH_DATA CI_END="4.299513280332315" CI_START="0.5929171117524863" EFFECT_SIZE="1.596638655462185" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6334192947354214" LOG_CI_START="-0.22700601561482492" LOG_EFFECT_SIZE="0.20320663956029822" MODIFIED="2013-06-26 18:56:23 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.505418086473712" STUDY_ID="STD-Mader-2003" TOTAL_1="66" TOTAL_2="45" VAR="0.2554474421347486" WEIGHT="6.425464498797502"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-09-29 14:24:19 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-09-29 14:24:19 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAm0AAAMJCAYAAABRGQFGAAB3FUlEQVR42uydD2SX3f//PyRJbonk
liQxk0kmZmaSicnk9pFIbsnXVyTJJDe3ycxMJJOZxCSZSeR2SzKRSZLbSDKTiUluk4lJkuT6eZ6f
8/6e99l1nXNd77233nu/Hw/e9t77uq7z57pe55zndf68zn8Sh//85z98GuhTa/BMsD/sjw8fyi8E
6im3woIGe/g19MyxP+yPtABQfiGHaOPmU/Ao/ID9AQBlp+bvOTcdI/gPhR6wPwCgDCHagEJHgQfs
D4DyC4g2oNEE7A/7A6AMIdqAQkeBB+wPAChDiDag0cT+sD/sD4DyC4g2oNEE7A/7A6AMIdqAQkeB
B+wPVpk3b96QDsovxETbly9fknPnziVbtmxJNm3alJw4cSL59OlT6fjCwkLy3//+1xzbvHmzOf7x
48fS8aWlpbrwotwIBlmLjWbM/ixfv35NmpqauPfYX9Xj/uOPP5JffvmlVL+pzrN8/vw5OX36tLHN
7du3J729van2Wa/3PnZdNZ+p7nFW2I8ePUo2btyYtLa2ViXe0PWhdDRyWaIOqxHRdvHixWR0dDT5
8eOH+agCU8Vl6erqSu7du1c6ru9HjhwpHX/48GHZ+TQo5LFI3DH7E9+/f0+OHz++rp8RFV5t2t+1
a9eSkZGRkv0NDg4mhw8fLh0/e/ZscvXq1dLxGzduGFvk3lc/3FBYEmyPHz9ek7j8Y4g26rCaEm3b
tm0zlZHbQLpvGiosaQXIokpOFVmRB//y5ctkx44dycGDB0u/DwwMJFu3bjU9Lnqbdfn27Zt529Wb
cHNzc/LixYtlb8q6TsdV4X748CEYn/J7/vx583a9c+fOZGJiIvWtbsOGDcn+/fuTqakpGs1Vijtm
f0LP9P3797nSj31hf0Xi3rt3r+ntzarfZIuufeq7nmuj2J97XSzcWD517u3bt5Pdu3ebuF0hljZS
4/7NOpYn3jzpdtOYFpfauLR0h5557LnFbFR5UppVR+rFwj0eSxOirY5Fm48qEBmf39NmuX//fnLo
0KHS/3rrVM+bCowMTIYae/AXLlwwBenff/81v928edMUZv2mRluFSm+3litXrph4bc/evn37Sseu
X79e9qassFQBhuIbHh5OhoaGzG8a6u3s7CwzSLcATE5OmoqdRnNt4vbtTzx58iR3GNgX9ldp3Jrq
oYby1KlTmaJN9um/VNSz/bnXxcKN5VPnHjt2rCRelAZXIId6uELHYvHG0p2np62npyeYbv8Z5Hlu
oXiVn8uXL5fS3NHRsex+hNKEaGsg0Xb37l1TiVhmZ2eN0rdvHvqu3yy//vqruca+0dy6davs+rQH
775xCM1TcCtG+wZsUSXmH7e0tLSYitStVDX3JBSf3obca6anp8sMUqLBVqI0mmsbt29/RcPAvrC/
SuI+efKk6RXR59WrV6Xf1dCqR0P2oXmVGs5Xz0aj2J97XSzcWD7T0ppXmIWOxeKNpTuPaIul2z+e
57mF4m1vby+bW+mnOZYmRFuDiLbFxUVTeeltxaI3I7012DcGzQEJzenQORJyRR683hD8bmm3Ygy9
QaRVoKG3t7TwlGb3PL196n9VBv39/TSaaxR3mv1VItqwL+yv0rg1UqAhQ4sWHcgm9Uy1EEbPLtbT
Vk/25/fQhcKN5TMmVCoVbUXvr5/uPKKtSLorfW7ub76N+WnOM7yKaKtz0aaG8vfffy9bGWqNx5/T
oTH6ELE30SLnxyq1tGMx445dIzRHQUMV3d3dppuaRnN1486yv2qINuwL+8sbt+wwZA8zMzNmXlSj
2F9ItPnHY/lcLdFWyf1dbdFWyXMrIpARbQ0u2tTDIbcL8/Pzy475Ak3GoyEEi7p8tSzeom5gTaYt
8uD1Zqv5JFnoDTdr+EDX+t3Q7ltKWnzqenavUUWcdX9ev35dN8Zaq41myP6qIdqwL+wvK24NFbov
Cv4wls+DBw/K5rzVu/35Q3ahcGP5XC3RFou3yP2olmgr+txU97m/tbW1ldmlhuwRbYg2w/Pnz83C
Anf83EUTLMfGxswbqCoWTerUShzLpUuXzORdO3yqCaBy4VDkwWv41U4U1Uf/u8vuNcdJXfri6dOn
yybq2jkn+ihu159XWnzj4+Nm1aud5KnFFu55Cl8rrMRaTPBs5EYzZn/VEG3YF/aXFbeGQzVEaJ/v
n3/+aT7us5JQE+/evTM9U5pf1Cj2514XCzeWz5jQUAeB5mlZsZNXtMXijaU7raMiKx15RVvsubmL
QbQyXtOQQgsRlB9EG6LNsGvXrqBzXE2+lXDTW4I+Emz6zT0uX0Y6pkUKKjyVPPi+vj6z+lThyIDt
Khwbh3x3ydA1wdOvNO3San00cXhubi4an+bm6Y1aq161ssc9T0MHiscupbYVHI1m9eOO2V81RBv2
hf1lxa2XUVu/6fn6q99lC5rIbue0xSbw15v9+eGHwo3lMyY09MJv25kioi0Wb550u4TSkVe0xZ6b
Fct6BrIrPQM/HAlNpVfD8UpzrIcV0dYgog0ayggaMm7A/rA/WM9I2OsFt1HLL6INaDQp8ID9AdQk
6hXUQhHre069dj97wRJlCNEGNJqA/WF/AB5yKK5heTvtSHPHs1whUYYQbUCjSYEH7A8AKEOINqDR
BOwP+wOg/AKiDWg0AfvD/gAoQ4g2oNBR4AH7A6D8AqINaDQB+8P+ACi/3O+ff8PfvHlTEzejVtJB
o4n9YX/rO+5GfZZA+YWfJNpiD6KaD8r16OyHLY/Q8hDd2tpalXhD14fSUc8FpBYbTewP+6u1/BQ5
13+WNHyr83xW877xTLhP60q0reWDCoXl7sW22nHl2RCYRrM24sb+sL9aFm1F80TDx33hGcGKRJv7
u7wva29R7eGm/c4mJiaWPShtDq/90LSfWm9v77KwtNHt7t27S/va2YYwbW9J92/WsTzx5km3m8a0
uLS5b1q67XHt17djxw7j8NBi95bTBsPa0FebDIcMPC1PSrOcJ46MjCzbzy6UpnppNLE/7O9n2l/s
2WmTeO1lqXuse9Dc3Jz89ddfmc8ydL69Rs9Je1HqnKNHj5btNRq73vYI65ns378/mZqaym2nPisJ
K08+fZvVBuw23zr/xYsXue3Nt82scp7HtkO2kSdsRBvUjGgbHh42G76rIvv48WPS2dlZdlyb1sqg
7dYaquC0ua4blgqybTzsprh5ehhCx2LxxtKdp6ejp6cnmG5tKq3w7UbE169fN5WBftNHaVSFlLfR
VH60LYlNc0dHx7L7EUpTPYo27A/7W2v7iz27AwcOJOPj46X7rHsuIZIVbp7z29vbk4WFBXP8wYMH
yZkzZ3Jf74qIycnJZO/evbntNNS7XDSsPPn0bfbKlSvJ/fv3zXdt0bRv375CZSBvOY/Zdky0hcJG
tEFNiTa9EeltyKI3QPe45vuoILi4Bd2+RVbSMIaOxeKNpTtPoxlLt3+8paWlLE59135xeRtNW3Fn
pTmWpnoUbdgf9rfW9lf02Qn1wBTJk3++27Mmu7LzKPNcL2FkhY9PzE59qhlWWj59+5FI88OspOzG
zo3Zdky0VdvuEW2waqLNf6NQAfOP+0MCsQqsGo1mLN5YuvM0mkXS7VdQaemIhelPYPbTnGd4q95E
G/aH/a21/eV5dhrmUy/RqVOnjFiO3aei5/tpCF2vHjH9L1HV39+/LJyQnfqsNKyV5rPSMrBS2y5a
1hAr3Id1I9r846EKYDUbzVi8sXSvRqMZizMWZqyxQLRhf9jf2os2/9w7d+6YHqKxsTGzibeG+kL3
qej5vsiIXW/FkoYXu7u7zTBgXjtNo9KwKsnnWom2lbxEIdoQbetKtKlb2R0qmJmZKTuuyapLS0tr
3mjG4o2lezUaTaXJH55yK1//mvn5+bLf2trazHwLy6tXrxpetGF/2N9a21/s2Wkyu/vs/fvoh5vn
/NnZ2bLntmvXrtzXu7x+/bqQnYYoGlbR+yKampqCw6PVEm0x20a0IdrqRrRpYung4GBpAmdXV1fZ
cU1+tpN29dH/WrWW1+C1akjzBWwlmbfRjMUbS7dPKB15C7LSoNVONk2jo6OmUnLf9uwk3/fv35vJ
raGJ4MpPo4s27A/7W2v7iz07rSK0qyIl6CQIQjYVO1/fjxw5kiwuLpo4ZVfuQoTY9erd0qpP4U+S
j9mpz0rCypNPHw2lakhWPH36dNlChGqJtphtI9oQbXUj2sS1a9fMhGYt9dYKIv94X1+fecvSW70a
ArsyKI/Ba/WRrrM9AnkbzVi8edLtEkpH3oIsrMsFfbRyb25urnTMVoIaZlBjqsrRD0eNhdIrVwNK
c6inpBFEG/aH/f2MBif07J49e2Ym4OteSmRo4n7IpmLn67viUFy6RgLOnfgeu17DmZo/Zt1RWNGV
105dVhJWnnz6fP36NTlx4oS5RvG6CzKqKdpito1oQ7Sta9EGtYEqNHeYpN4KHfaH/WF/UK+2jWgD
RFudozd7TQC2fpDUa+JOBKbRBOwP+4P1YduINkC01TlacSUfUeq2l9fuS5cumQqGRhOwP+wP1pdt
I9oA0QY0moD9YX8AiDZEG1DoKPCA/QEAZQjRBhQ6CjxgfwCUX0C0AY0mYH/YHwBlCNEGFDoKPGB/
AEAZqj/R9ubNG+4uhY4CD9gfAOUXfoZoK3JuyNM0D55Ct9px59k5oNGeY63eh1rdkWNiYmJd3MO1
SNOXL1+Sc+fOmV02VLdrB4NPnz6Vjuu7dkfQ9l065+TJk2X7fFrk0NbdVi0NfxcFoP2ANRBtRR8k
D55Gk4qkMfNcq6JNPr0kMhBtSXLx4kWzj63dc1SOaSXcLAMDA0l/f3/p+N27d812Vy7yiXb8+PFg
erUfbmxPUKD8ItpSUME7f/682WNO+7TprdM99927d6U3K+0Z19zcXNooWOe5n9j59hrttae9EnXO
0aNHy/agi12v/fHsnor79+9PpqamyvKjSkV7zuktsLe3lye/DkSb3UNTz1wVubsXo67TBtDaoNru
kWg3QvfD9b+HritqKyuxuzxlQvtA7tixwwgIoQ3IbRnR+S9evCg7X5vF570nee6Dyr8ckY6MjNSl
wA6Jtlu3bhkhEjo/zUY/f/5stkfyBZ+enWwkj20onrGxMePFX/f/3r17ZnN2PY+05xqqO/PE5duZ
j9KgNsEVYO5oivZK1Qbx7nGlw0X3R6Is9Ly7u7uTt2/fIgRoP6CoaBseHk6GhoZMQVU3d2dnZ9nD
OXDgQDI+Pl56s1KlrkKf9SDznN/e3p4sLCyY4w8ePEjOnDmT+3q3IpucnDSbFlu0MbAaKLt9iQSo
NnSG2m001UDpGdvnrWeoRsm9ToLHCjm7EXoe0Ra6rqitrMTu8pSJCxcumGN2U+4rV66Y4SOhLXm0
Kbd7fk9PT+57EroPSre2+LHlv6Ojo+FEm2hra1v2spDHRjWUqON+nSrxlMc2FI/qPx37+++/jVg7
e/as+T/tuYbqzjxx+XYWQwLUtVWlzxV19jcX7UgQuufazF33EyFA+wEViDa9calgWvTmFns4emMv
8iD98923Q1UAra2tua9XBWIbMx+F41cobuOKEdReo9nS0lJmf/quXge/dyErrND30HVFbaXadueX
CT+tEml+mJXek9C5VgQUKf/1KNqePXtm5melnR+y0dnZWdPbZp+V/u7Zs6d0z2O24T8f/b+0tJT5
LEN1Z9G48qDhT71AuC8vaS80ee/5P//8Y3rrEAK0H1ChaPMLnAq9f6661FVwT506ZSqw2OTvouf7
aQhdr14O/a8Kyh/SUDj+kK3bOGIEtddopj2frF6joqItdF1RW1mp3a20TMTuZaX3wV9IlFb+G0G0
CYk2iTf/95iNHjp0yPRwCfWoqmczr2346Qr9H7OTonHFWFxcNPfE3bczdi9CedFwsjoJ3JcEhADt
B6xQtPkP586dO+atX/Mu1O2tbvVQRVL0fL/hiF1vG0ANGWlehIZ2QhUK1HajGbO/1RJtldhKpXZX
SZlYK9GW56WtUUSb5mFpmDR2j/zjsgnNOxSay2aHB/PYxkpFm1t3Fo0rhITa77//vmxlqD8UmvVb
WnwaytWQLkKA9gNWINo0POJ2/WuSqXuuCqTbXT8/Px+sSPKcryEFi+LW8ELe611ev35ddkwVpnst
1H6jqWfmDz25DdFqibaV2EpRuytahoTcJYSGR6sl2iRS3Ib51atXDSvahHpRtTDBf74hGxVa6KG5
bBoa9e07ZBtFRVuo7iwaV6iHTXP1ZKc+emGRWxCLFmFo4UHevGV9gPYDcoo2dedrYqidiNzV1VX2
cFQZ2ZVuEnSq5N3jWsWkeRK2Uoudr++a06CKQXFqEYQ7mTZ2vXostJJP+BN1NSHYLqrQR/9nVSgU
utqIW89IKyHtM5O7Ade/02qJtqK2shK7y1MmfDSUqiFZ8fTp02ULEaol2vyFCKvphmE9iDaJEA2B
+7YSslGhCf9afe8vZonZRlHRFqo7i8aVxvPnz81wrzuE6aIFFm4c6j32pwsUiQ8hQPsBBUWbuHbt
mplYq6XiWoHknqs5HprMqkZKDYfvEFGVlN467Ztn7Hx9VxyKS9eoEnInx8au1xCV5gRZ9wW2IbXI
Z5B6NhS25pbkXSVFoft5cVt3CvpoVd7c3Nyqi7aitrISu8tTJnwkHuQfS9coXncCejVFm9BLm8qj
RIfKZlGH2fUk2oTv9ihmo7Z3SvctzdFsyDaKirZQ3Vk0rjTUcxfqCVN4erG3db5WMbvOdxFttB+w
BqINKHQUeLBi0R1yw/4AgDKEaANEG9QA6mHXRHrr20s9Su4iC+wPAChDiDZAtEENoJWOcsOgoS55
w7906VKZiwfsDwAoQ4g2QLQB9of9AVB+AdEGNJqA/WF/AJQhRBtQ6CjwgP0BUH4B0QY0moD9YX8A
lF9EG1DoKPCA/QEAZQjRBhQ6CjxgfwCUX6h70RZLI0ZTn42mtmuSZ/WfiXY40O4Drhd4bdE2NTVV
s89IHu+1xRX2R4MDQBlCtGEUFLo1iVt7PbobYa812ktUAk1/XbRfqLYEevHiRU0+I90z+VjD/qhb
AChDDSLabA+D9lTcv3//sp4FbRCsve60515vb2/ZsXfv3pm3fTV4CqO5ubm0MbZ9yNqzcceOHaXG
RRvLa+8+XaPz3QZR52tjZm2wbfd4dBtSfx8+bXadda5NuxpdOQ0dGRlpeKOrxUZTG1RrD0WfkN2l
sZJnnbaXqCvctG+oi92HUjasDbn9/R9jx0Np9dMduw+6d7qH2B8NDgBlqAFEmyt2NEzlNlDanFjC
yG5xo42UtUG85cCBA8n4+Lg5ro8aIAk09yFfuHDBHLMbF1+5csVsmC20fY420HbP1zCZbeSULqUv
S7RJMGadq3RrOx7FrU2cOzo6EG012GhevHgxuXPnTtlvMbvzWemzjp3r7hBw/fp1Y+fW5pVWvYTk
PR5Lq/s9z30YGxsz9xD7o8EBoAw1gGiTyLIiykfDVmowXPxeBx/1erkP2e9lkEjzwwydn9Wgxc5t
b29PFhYWSv9PT08j2mqw0Wxra0tmZmZWZHcrfdZFzm1paTG9xRZ91/6deY/H0up+z3MfdO90D7E/
GhwAylADiDb1rumYGoj+/v6yY/7EbH1cUSY0/Knes1OnTpkGKzTUY8MsYhQh0RY6V3spuqjxQ7TV
XqOpIURfmOSxO5eVPussW3I/aS8laTYdOx5Lq/s9z33Q9Ro6xf5ocAAoQw0g2qzw0lBld3e3GboJ
NUAuGtZSz5mGaLTxtIZAa0W0+fEg2mqz0UyzsZjdxWyqGqItr12t9HhItOW9D6Eyhf3R4ABQhupM
tFlev35d9mC0MGFpaSnzfE2mdo/Pz89HhVVTU1NweLRaok1DRpozZHn16hWibZ30tMXszmelzzpt
EYvFnyuptPnDn27vWex4LK1Fyp/QXDd62mh0ACg7DSLa1FNmV875DZQmVQ8NDZUmVet/rYazaOWm
XS1q59bEhJWGUjUkK+Rjyl+IUC3R5k/4VroRbbU5p03zulxiduez0med5fJD5UK/uytLlRatcLZp
Gx0dNS8ieY/H0up+z3MfJPqY00bjA0CZaRDRpqFRzUWzbjN81wd9fX2mR029BVqtaVeBimfPnpmJ
0bpO4ksLGmLC6uvXr8mJEyfMNYrXbbCrKdrE4OCgcZewc+dOsxLPn09E4fv5cWvlo56NT8juKnnW
sbzbFxZ3/lhWD5x16aGPVobOzc0VOh5Kq5/O2H24desWq0crSAcfPnzyfaDGRFujILG4a9cuRFuN
xS0/faFetHp/1itNa2dnp3nxwv6A+gkA0bZukZsFLa6wPq7U++EusqBSrJ24tXL5zZs3DfGsq5lW
TUnQvcP+gPoJANG2rtFqVu3CoGEleZ6/dOlSmZNUKsXaiVtDkL/99ltDPOtqplX3jL1HgfoJANEG
VIpUyIANAPYBgGgDRBtgfwDYBwCiDRBtgP0B9gGAaAMqRSpkwAYA+wBAtAGiDbA/wD4AEG1ApUiF
DNgAYB8AiDagUqRCBmwAsA8ARBsg2gD7A+wDANEGVIpUyIANAPYBgGgDRBtgfwDYBwCiDRBtgP0B
9gGAaAMqRSpkwAYA+wBAtAGiDbA/wD64CQC2PFAoqBBJA/DsARsBWCeijYJBZUhagGcO2AnAOhFt
tnDwaZxPLVbOfLA/AEQbQA7RRqUAgP0BUD4AEG1UCgDYHwDlAwDRRqUA2B8A5QMA0UalAID9AVA+
ABBtVAqA/QEA5QMA0UalANgfAOUDANFGpQCA/QFQPgAQbVQKgP0BUD4AANFGpQDYHwDlAwDRRqUA
gP0BUD4AEG1UCoD9AVA+ABBtVAoA2B8A5QMA0UalAID9AVA+ABBtVAqA/QGs83LhfwAQbUBlANgf
AKINANFGowmA/QGsVLgBAKKNRhOwPwBEGwCijUYTAPsDQLQBINpoNAH7A0C0ASDaaDQBsD8AygcA
oq1m3+b48PkZHwBAtAEg2oBKFYCXNz58eNFEtAEg2gAbBqDMAKINKLwA2C8AZQcQbUDBBWwXAChD
iDag0AJguwCUIUC0AYUWANsFoAwh2gAotIDtAgBlCNEGFFoAbBeAMgSINqDQAmC7AJQhRBsAhRaw
XQCgDCHagEILUBO2+8cffyS//PJLsnnz5uTEiRPJwsJC6djnz5+T06dPJ5s2bUq2b9+e9Pb2Jp8+
faLs/sS0/OzrKUOAaIOaL6xsbQL12OBcu3YtGRkZSX78+GE+g4ODyeHDh0vHz549m1y9erV0/MaN
G8nx48dpcBFtlCFAtAGiDWAtG5y9e/cmX758Kftt48aNpe/qYZNYs+i7euVC8bx8+TLZsWNHcvDg
wdLvAwMDydatW5MtW7aY3jqXb9++md489fQ1NzcnL168KDuunkBdp+MSlB8+fAjGpzSeP3/epHPn
zp3JxMREWf4fPXpk8rhhw4Zk//79ydTUVPDeZaX95MmTydOnT8vCPXr0aDRPblrSnov7WywvsXub
53pAtCHaoK6FG0A9NjhLS0tGAJw6dSpTtEmM6LdQPBcuXDDX/Pvvv+a3mzdvJrdv3za/ff/+3QgH
9d5Zrly5kty/f998f/jwYbJv377SsevXr5f1BCosiaFQfMPDw8nQ0JD57ePHj0lnZ2dZ/iXYHj9+
bL5PTk4a4ZpFKO2Kr62tzRz7+vWrCWd2djaapyKiLZaX2L2NXQ+INkQbINoA1lmDo14j9dTo8+rV
q9LvEkgaErXC5OLFi6aHKhSP2xMmWltby4SfcIWSBI1/3NLS0mKEoisaNbcuFJ963Nxrpqeny/Kv
XjkrqGLE0i7RJGEkoaR7kydPRURbLC+x9MWuB0Qbog0QbQDrtMHRUKSGDC1adCBBp96ppqYm0zMV
62nz0bX+9AJX+LnDsT5pAtE9Pys+F4ka9zzlQf9L8PT39wfvRyztVjhJSC4uLubKUxHRFstL0Xvr
Xw+INkQbINoA1mmDoyG2kOCYmZkxc6OKxBPqmYsJnLRjMdETu0ZoHpyGLbu7u5PLly8XEo0+PT09
pmdtLUSbf7ySe0sdhmhDtAGFFmAd2q6GCjXXyeIPP/o8ePCgbM5bnnjUc6f5clmoBy9rKFHX+sOj
bk9fWnzt7e1l10hoZuX/9evXwXIdS/vo6KiZUzY2NlY2PBrKU0i0zc/Pl/0Wy0ssfUXuBVD/I9qA
QgtQw7ar4VANEdqJ/n/++af5WNSDJKEm3r17Z3qmNC+qSDxaTGAnw+uj/123Ipq0ryFLodWY/kIE
O6dOH4kkCaJQfOPj48Z1iZ1839XVVXaewtdKT6EFCaFesVDatRCho6OjTEC9ffs2mqesRRHv379P
jh07VnY8lpfYvY1dD9T/iLYqGQcfPnzyfaDyBkfDoVp9qd4rLUKQiHORQNNkdjunLTaBPyuevr4+
43ZC8UiY2JWeQgsc5NRXcWjhgS8KrcsPfbQwYm5uLhqf/M+px1CuMLRYwD1PQ6OKR0OLitMKuCyy
0q40uy4/9F3HY3ly02JFo9Ki+6u0+HkK5SV2b/NcD4g2RBuGAUCZ4R4BUIagfkUbRgFA2eH+AFCG
EG0YBACVKvcGAChDiDYMAoAyxL0BoAwBog0AKEPcGwDKEKINgwCgUuXeAABlCNGGQQBQhrg3AJQh
QLQBAGWIewNAGUK0YRANxps3b7gJ6/Q+UIa4NwCUIUTbTzWIL1++JOfOnTPewOXxWl62P336VHbO
xMREsmfPHnO8ra3N7KeXhryZr1fDW610ywO5PJK3traa/919DddLfmIbUFfCWt0HKlXuDQBlCOpG
tGkTYu23Z/eW05YuEm6Wf/75x2wKrI2GdVx7zbn73Fm0r532pEO0lePu/beWBXO1RFsjV1BUqtwb
AMoQou2nGsS2bduMGLNor0C3F+TUqVNmb7kY2uhZmxnHDE/HtTffjh07zJ6DloGBAbN3nXr8ent7
y6759u2b2RNw8+bNSXNzc/LixYuy43bvQB2XcPzw4UMwPuX3/PnzZj+9nTt3mp5EN922d0z79WmT
5qmpqcz8aJNr7cenuHWN0vfXX3+V4s6zp2Uo71n3yyWWn7Rn4h+/c+eO2T9QadBekdrbMOvcPM+l
yH3Jcx+KPBMqVRocAMoQ1KVo81FDLIFg2b17d3T+0eDgYDIyMpIrHh2XKJDQsBsPa5Ph27dvm98k
GiU6rl69WrrmypUrpY2kHz58WNbTd/36dRO37SlUWBISofiGh4eToaEh89vHjx+Tzs7OsnS7vWOT
k5PJ3r17M/Nz4MAB0/to41da3Pvn3w///1je09LvE8tPHtGm4VuJXYUh8aQe2JhoCz2Xovcldh+K
PBMqVRocAMoQNIRou3v3rmmM3cZSjaR6StRr4s950/DpkSNHcsej425PmJBgcHv7hNsoSwz4xy0t
LS1GaLqiUz1GofjUY+VeMz09XZZuiQsrRipBvUF5RVss72np94nlJ49oc3vJNM9x165dUdEWei5F
70vsPqz0mVCpcm8AKENQV6JtcXExOXnypOnpcK/TQoWlpaVST5aGTMXnz5+NYFhYWCgk2nwkDP0h
M7eB1/E8QiDt/Kz4XJQv9zyJVNv71N/fH71vGr6U0NV9kYgMCSb//1je8zy3WH7yiDZfMGXdQ79H
slr3JXYfij4TKlXuDQBlCOpWtEmo/f7772Z4zUXzpNxeHDXuds7bmTNnkgcPHhSKJ+14mvAKiZLY
sZhgiV1jBYeG/DRX7/Lly5nxay6YepzGxsaSJ0+emCHMIqItlvdKRFuee1DkHlUi2orel9h9KPJM
qFRpcAAoQ1C3ok09bOpN0wpRn6NHj5b9L9GmYVIbZmySfZ50aGK5evKyaGpqyhyG07X+8Ki7kCIt
Pq2Gda+ZmZnJTLPcm4TyI1Hrpl33sIhoi+U9T0GO5ccPIy2NrhsXDX8rXzHRFnouRe9L7D4UeSZU
qjQ6AJQdqEvR9vz58+TQoUNlQ5wumkekj51QfuPGDeOrrVLjSzuuxQR2Ir0++l+rQC0aYtPwmHj6
9OmyhQhKk71W7kskJkLxaYK8Fk/YiftdXV3L5mpptaLQ5PdQj5IWathVkRJLujchcSLBqzlqVmTF
8p6nMMfy407il2sWrer006g4da3C+PPPP5Pjx49HRVvoucTuS9H7UOSZULHS+ABQZqAuRZsmnMd6
yiSKNBFcPVhq8OXao5qiTfT19ZneGRuHu1JS7ie0AEINteZGaaK9i3X5oY9Wjs7NzUXjkxsTLViQ
iwnN03PP0zCc4tGQneK0YiGNZ8+emQnzOk/Cwncw7MevFZHKo9sbGMp73gIdyo8VOcqPBK3y46dR
AuvXX381z/nSpUtli02y8hN6LrH7UvQ+FHkmVK4/v67hw4dPvg8g2mhwANvgPgFgvwCINqAy5z4B
YL8AiDYKLKw563EfUMoQAPYLgGgDAMoQYL8AiDYKLACNHgD2C4Boo8ACUIYAsF8ARBsAjR4A9guA
aKPAAlCGALBfAEQbBRaAMgTYLwAg2sgnYFsA2C8Aoo0CSz4B2wLAfgEaXLTpd+3rqD0nDx48WPp9
YGDA7GOp/Tx7e3uXXTM2Nmb2uty2bVty7949s8G39o10Nye32L1BtUm4NgHXRuGfP382+55q/0oX
bSC+f//+XOnQxuLnz5838e7cuTOZmJigYgIaPQDsF6B+RduFCxeMALIbdGvD8du3b5vfvn//bsSQ
Nvh2rzlz5ow59vfffxvRdPbsWfO/3ZzcIjE3MjJiwtJHYWtTd3Hu3Dlz3GV4eNgItTzp0LlDQ0Pm
+MePH5POzk4qJqDRA8B+AepXtKnny6W1tdUIIZe9e/dmXqP/l5aWUuNqaWkxvWcWfVcPnZidnTW9
bTYu/d2zZ08p7Fg61DPohj09PU3FBDR6ANgvQP2KNh/1lOl397Nhw4bMa0L/u9e54VsOHTpketPE
+Ph4cuzYsdzpcMOxoo+KCWj0ALBfgIYRbWlCK69I8//3hZV//OHDh0lzc7P5rrlsT548yZ2OWNgA
NHoA2C9AXYs2iSd3uHMlok1h+cOjmzZtKjt/9+7dZn6ahkaLpKO9vb0s7JmZGSomoNEDwH4BGke0
aXGAneCvj/7Xqs9KRJuuvXHjRims0dHRpKmpqex8LS7Q6k93kUGedGg4dXBwsLQQoauri4oJaPQA
sF+AxhFtoq+vz6wKVa+Y5pnZlaVFRZuwLj/00crRubm5suOLi4smHgmvIukQ165dMwsb5BZEq02p
mIBGDwD7BahL0QYAlCHAfgEQbRRYABo9AOwXANFGgQWgDAFgvwCINgCgDAH2C4Boo8AC0OgBYL8A
iDYKLABlCAD7BUC0AdDoAWC/AIg2CiwAZQgA+wVAtAEAZQiwXwBEGwUWgEYPAPsFQLRRYAEoQwDY
LwCiDQAoQ4D9AiDaKLAANHoA2C8Aoo0CC0AZAsB+ARBtADR6lCHAfgEQbRRYABo9AOwXANFGoQWg
7AA2DADrSLRRcAEoM4AdAyDa1lnh5cOHT74PAKINANEGQKUKANQvAIg2oFIFAKB+AUC0AZUqAFC/
ACDagEoVAID6BQDRBlSqAED9AoBoA6BSBQDqFwBEG1CpAgBQvwAg2oBKFQCoXwAQbQBUqgBA/QKA
aAMqVQAA6hcARBtQqQIA9QsAog2AShUAqF8AEG1ApQoA1C8AgGgDKlUAoH4BQLQBlSoAAPULAKIN
qFQBgPoFANEGQKUKANQvAIg2oFIFAKB+AUC0AZUqAFC/ACDaAKhUAYD6BQDRBuuyUuXDhw+f1foA
AKINAOg5AQBAtAEAINoAABBtAIBoAwBAtAEAINoAABBtAIBoAwAARBsAINoAABBtAACINgAARBsA
INoAAADRBgCINgAARBsAAKINAADRBgCINgAARBsAwOqLNfaUBABAtAEAog0AANEGAFBt4QYAAIg2
AEC0AQAg2gAAEG0AAIg2AEC0AQAAog0AakG4AQAAog0AEG0AAIg2AKiueOHTOB/A7rF7QLQB0NsE
PHPuAfDMEW0AQCUGPHvyDjx7RBsAlRdgA+QZsAFAtAFQcQE2QJ4BG0C0AQAVF2AD5BmwAUQbABUX
YAPkGbABQLQBUHEBNkCeARtAtAEAFRdgA9g9YAOINgAqLsAGyDNgA4g2AFj7iuvLly/JuXPnki1b
tiSbNm1KTpw4kXz69KnsnImJiWTPnj3meFtbW/L69evUsO7fv79uK8hGqNgRbcXsPmTXRa7HJsgj
og0AqlJxXbx4MRkdHU1+/PhhPn/88YdpgCz//PNP0t7enszPz5vj4+Pjyb59+5aF8/79++Tw4cOI
NvJYF3Yfs+u812MT5BHRBgBVq7i2bdtmGh3L9+/fTc+B5dSpU8m1a9ei4Xd3dydv376NVpA6/vLl
y2THjh3JwYMHS78PDAwkW7duNT0Xvb29Zdd8+/YtOX36dLJ58+akubk5efHiRdlxNZi6TsfVwH74
8CEYn/J7/vz55Jdffkl27txpehLddD969CjZuHFjsmHDhmT//v3J1NQUjVeD2X3MrvNej91j94g2
AFi1iksNhSp6y+7du5M3b94ErxkcHExGRkZyxaPjFy5cMA3Iv//+a367efNmcvv2bfObGj81Jlev
Xi1dc+XKFTNEJR4+fFjW03f9+nUTt+3xUFhq6ELxDQ8PJ0NDQ+a3jx8/Jp2dnWXpVsP1+PFj831y
cjLZu3cvjVeD2X1Ru067HrvH7hFtALCqFdfdu3dNY+FW5KrA9aavN3p/7o6GT48cOZI7Hh13ewRE
a2trWa+FcBsMNVb+cUtLS4tpMN3Gc/v27cH41PPgXjM9PV2WbjW+trFsRBvA7ovbtX89do/dI9oA
YFUrrsXFxeTkyZPmrd+9ThOul5aWSm/0GjIVnz9/Ng3BwsJCIdHmI2Go392Phmjc41m456WdnxWf
i/LlnieRqv/VqPb399N4NZjdF7XrtHKD3WP3iDYAWLWKSw3O77//boZNXDT/xX07V0Vv5+6cOXMm
efDgQaF40o6nNUChxiZ2zI0jT+OVdp7mA2lISnOaLl++TOPVQHZfxK6zyg12j90j2gBgVSou9RSo
N00rRH2OHj267O1cw6Q2zKxPkXRo0rN68rJoamrKHCbStf4wkTshPC0+rYZ1r5mZmclMs9yb1Eul
j2jLZ/d57TpUbrB77B7RBgBVr7ieP3+eHDp0qGwoyEVzXPSxE55v3LhhfLVVWkGmHdekajtBWh/9
r9VwFs0V0tCNePr06bIJ2UqTvVZuGNTYheKT2xJNMrcTsru6usrOU/haSSc0MTvU40HjVZ92Hwtn
pddj99g9og0ACldcu3btivYoqHHQJGW9yR87dsy4QKimaBN9fX1mKNbGYVe8ia9fv5oFEGpENAFb
E6hdrOsDfbSCbm5uLhqf3Jho4rbcLWiennuehogUj4avFKdtyGi8GsvuQ+Gs9HrsHrtHtAEAFRdg
A9g9YAOINgAqLsAGyDNgA4g2AKDiAmyAPAM2gGgDoOKiyGEDiDbA7gHRBkDFBdgAeQZsANEGAFRc
gA2QZ8AGEG0AVFyADZBnwAYA0QZAxQXYwGrmqRL/aIDdA6INgIoLsIGfINqynNxi94ANINoAqLjI
97q9F6G9Nevxs15s7WdfTx0AiDYAKi7yzb1Y1TzVSk8bog27R7QBwKpWXNpfUPsMar/B/fv3J1NT
U6Vj3759M3sabt68OWlubk5evHhRFp72KtSepAcPHiz9PjAwYPY11H6Ivb29y+ILHVeYt2/fTnbv
3l3a/1AbV+e9Xhthnz9/3uzluHPnzmRiYoIKu0FEWyV5zrKlkydPmg3a3TJy9OjRXGUiFK/7Wx5b
xdaxe0QbABVXGa4wmpycTPbu3Vs6duXKleT+/fvm+8OHD5N9+/aVhXfhwgXTeNhNrrUBtUSXfvv+
/btpSK5evVq6JnZcYWrT7A8fPpj/lS6lL+/1w8PDydDQkDn+8ePHpLOzkwq7wRuvrDyHbEn23NbW
Zo5p03aVidnZ2VxlIq9oi9kqto7dI9oAqLiWoZ4y2wj5qEFSo5AVnhVXltbW1mXnuyIwdjwtTDfd
sevV46eeEMv09DQVNqIt9feYLUk0SRhJKF28eDF3mcgr2mK2iq1j94g2ACquZah3TcfUSPT395cd
c3u58oSn8/25RRrmzHs81tDlCd9FjR4VNqItjZgtWeG0ffv2ZHFxsXCZyGPLIVvF1rF7RBsAFVcq
mpumoZ7u7u7k8uXLFYs2v9ErejzW0MWuT0svFTairRJbFD09PaZnbS1EG7aO3SPaAKBQxfX69euy
85qamnINBVm0kGFpaSkz/NjxWEMXu769vb1syGhmZoYKG9FWkS2Ojo6aOWVjY2Nlw6N5y4Qf7/z8
fNlvMVvF1rF7RBsAFdcy1JOg1XHCn/ivSdcaPhVaTZc16dpy/fr10uRoffT/4cOHcx+PibbY9ePj
48ng4GBpcnZXVxcVNqIt9feQLWkhQkdHR5mAevv2baEy4S7wef/+vVlg4x6P2Sq2jt0j2gCouJah
odGWlpaSiw0r4IRWzp04ccL8rnM02TkWXl9fn3FDsGnTJtNQ2ZWleY7HRFue8K9du2bmIclVgiaT
U2Ej2rLIsiXZvOvyQ991vEiZsC9AKlfqnVO58tMSs1VsHbtHtAFQcQE2QJ4BGwBEGwAVF2AD5Bmw
AUQbAFBxATZAngEbQLQBUHEBNkCeARsARBsAFRdgA+QZsAFEGwBQcQE2QJ4BG0C0AVBxATZAngEb
QLQBABUXYAPkGbABRBsAUHEBog2we0C0AVBxATZAngEbQLQBABUXYAPkGbABRBsAFRdgA+QZsAFA
tAFQcQE2QJ4BG0C0AQAVF2AD5BmwAUQbABUXYAPkGbABQLQBUHEBNkCeARtAtAEAlRfw7Mk7ds+z
R7QBUIkBz5x7ADxzRBsArEllxqdxPoDdY/eAaAMA3rwBABBtAACINgAARBsAINoAAADRBgCINgAA
RBsAAKINAADRBgCINgAAQLQBAKINAADRBgCAaAMAQLQBAKINAADRBgCAaAMAQLQBAKKNmwAAgGgD
AEQbAACiDQAA0QYAgGgDAEQbAAAg2gAA0QYAgGgDAEC0AQAg2gAA0QYAgGgDAEC0AQAg2gAAEG0A
AIg2AEC0AQAg2gAAEG0AAIg2AEC0AQAAog0AEG0AAIg2AABEGwAAog0AEG0AAIBoAwBEGwAAog0A
ANEGAIBoAwBEGwAAog0AANEGAIBoAwBEG9UOAACiDQAQbQAAiDYAAEQbAACiDQAQbQAAgGgDAEQb
AACiDQAA0QYAgGgDAEQbAACiDQAA0QYAgGgDAEC0AQAg2gAA0QYAgGgDAEC0AQAg2gAA0QYN+Pz5
NM4HEG0AgGgDnj3wzBFtAABU4sBzB549og0AqMC5CTxzwAYA0QYAVN7AMwdsANEGAEDlDTxzwAYQ
bQBA5Q08c8AGANEGAFTewDMHbADRBgBA5Q08c8AGEG0AQOUNPPOfyJs3b2oqnNUOExtAtAEAUHnz
zJfx9evXpKmpKXjO/fv3o+E8evQo2bhxY9La2lo4XbGwN23aVJV7Ua1wQmHmLWNrWRYp94g2AEC0
wTp/5t+/f0+OHz8ePOf9+/fJ4cOHo7Yjwfb48eOK0hULu1p2uxr2X2mYiDZEGwAAlTfkfuYSYxJl
oXO6u7uTt2/fBs9J2/My7fwsoVY0bDEwMJBs3bo12bJlS9Lb21v6/eTJk8nTp09L/6sH8OjRo7n2
5Xz37l1y7NixZPPmzUaENjc3J3/99VdZWl6+fJns2LEjOXjwYDTf3759S06fPm3CU1gvXrzIzHNW
fmwelJ4NGzYk+/fvT6ampij3iDYAQLRBIz3zJ0+eBM8ZHBxMRkZGctmOf7xaoi3t+M2bN5Pbt28n
P378ML2FExMTydWrV82xf//9N2lrazPHNPS7d+/eZHZ2Nlc8Bw4cSMbHx821+ijvEmhuOi5cuGCO
KZ5Yvq9cuWKGlsXDhw+Tffv2pZ4Xyo9wezEnJydNnij3iDYAQLRBAz7ztHP++eef5MiRIxULq9UU
bZo3J4Hj4goZiaDh4WEjfC5evLgi+1fvlnv9hw8fcudbIs1PZ9p5sfxIOFrxR7lHtAEADTgg2kp8
/vzZDP8tLCzUpGhTz5M/NOmKKyuEtm/fniwuLha6Fxr+VA/ZqVOnkpaWlmg6Q/lWOvPkKZYf9a7p
N+Wpv7+fco9oAwAacEC0/X/OnDmTPHjwoFA41RBtWfPO/LB8gZZGT0+P6ekqItru3LljrhkbGzND
xxoCXQvRlic/EpMaYtUcw8uXL1PuEW0AQAMOiLbl4ik2gT+PaJufn69aT5sm4y8tLWWePzo6auaI
SXwVGR795ZdfysINpTlPvuVKJc/waCw/Lq9fvy5cjin3iDYAQLRBnYq2Ss5JG8K0k+e1QlWrMisV
bVp9qblkWo0prl+/ngwNDZUWDOh/rYQV6h3r6OgoE0Ra/ZoWjs/u3btLq0VnZmbMgoZYOv0w/YUI
GtoUWtGatRAhlB+h67SCVOiehnrwKPeINgBAtAGirdBxKy409KceJ4mOSkWbFhTIia3ryLavr8/0
jOk3CUK7mvPEiRNlLj/0XcezwnF59uyZWQCgdEso+U6F09Lph+meo9WrSo/C0/y46enpzLCy8iM0
NKrrdS8VlhVwlHtEGwAg2oBnDtgAINoAgMobeOaADSDaAACovIFnDtgAog0AqLyBZw7YAKINAIDK
G3jmgA0g2gAAqLx55oANAKINAKi8gWcO2ACiDQCAyht45oANINoAgMobeOaADQCiDQCovKExnvlK
4/rZ12MDgGgDACpvQLQh2ij3iDYAACpvqOyZDwwMJFu3bk22bNmS9Pb2ln4/efJk2f6d2uvy6NGj
5rs2Rj99+rTZKL25uTl58eJFalxp8bq/aWP08+fPm/02d+7cmUxMTCy7Jit9ea7H1in3iDYAoPKG
unjmN2/eTG7fvm3Ez/fv343o0ebnQpuVt7W1mWPa9FybqM/OzppjV65cMRupi4cPH5qN1SsRbcPD
w8nQ0JCJ4+PHj0lnZ2fZ8VD68lwPlHtEGwBQeUNdPPPW1lYjeFwkzlzRJGEkoXTx4sXS7xJp/nWV
iLaDBw+aXjvL9PR02fFY+mLXA+Ue0QYAVN5QF89848aN5pj72bBhwzJht3379mRxcbHsujxxxUSb
H44Emn88lL7Y9UC5R7QBAJU31MUz9wVaGj09PaZnbS1Em388lr7Y9cB9QbQBAJU31MUz379/f7K0
tJR53ejoqJlTNjY2VjY82tTUVNHw6Pz8fNlv7e3tZcObMzMzZcdj6YtdD5R7RBsAUHlDXTzz69ev
lyby66P/Dx8+bI5pIUJHR0eZgHr79q35roUIk5OT5rtWmGYtRFBP2OPHj8339+/fJ8eOHSs7Pj4+
ngwODpYWEnR1dZUdD6Uvz/VAuUe0AQCVN9TNM+/r6zMuMzZt2mRElcSaOHHiRJnLD33XcaHVpDou
UdbS0mIWAKTFJcGmczTMqd45uQ3x03Lt2jUzZ05uPbTwwT+elb4812PrlHtEGwBQeQPPHLABRBsA
AJU38MwBG0C0AQCVDpU3zxywAUC0AQCVN/DMARtAtAEAUHkDzxywAUQbAFB5A88csAFAtAEAlTfw
zAEbQLQBAFB5A88csAFEGwBQeQPPHLAB7iO3AACovIFnDtgAog0AgMqbZ85NwAa4CYg2AKDyBp45
YAOINgAAKm/gmQM2gGgDACpv4JkDNgCINgCg8gaeOWADiDYAACpv4JkDNoBoAwAqb+CZAzYAiDYA
oPIGnjlgA4g2AAAqb1ijZ/7mzRtuMOUe0QYAQOUNq/nM9fvExMSKbGTTpk0/zQZ/ti2vp7JEuUe0
AQCiDda5aDt48GDy9evXim2kEnuqFxtEtCHaAACovGHNRNutW7eS/v7+4Pl//PFHsmXLlmTz5s3J
4cOHkw8fPpTOcz9p/PjxIzl//nzyyy+/JDt37jQ9e/65AwMDydatW00cvb29ZccePXqUbNy4Mdmw
YUOyf//+ZGpqKjOdCkfxbNu2LRkZGSk7ru+3b99Odu/ebcJSmI8fP86djjz5oNwj2gAAqLxh1USb
aGtrKwkx//zr168bASTRos/NmzeT06dP57an4eHhZGhoyFz78ePHpLOzs+wahScxpePfv383Yujq
1aul4664mpycTPbu3Zsat8K4fPlyKZ6Ojo5lou3YsWOlfCpMhZ03HbF8UO4RbQAAVN6w6qLt2bNn
ycmTJ1PPb2lpSb59+1b6X9+3b9+e2540/OpePz09XXZNa2urEUIurjDbsWNHcv/+/Wi+2tvbk4WF
hcx49N0Vpv71sXTE8kG5R7QBAFB5w6qLNiHRJvHm/66hRB+3hypmT+65QsLIvUbH/WFWN071ruk3
iarQMK6/IMKPJy2dRdIRywflHtEGAEDlDWsi2t6/f2+GSdPETOi6oqItjyj0efnyZfLw4cOku7vb
DIFmia6ViLZYOmL5oNwj2gAAqLxhTUSbUE+WFia4v2vyvz886vZqxexJw5bu9TMzM8vCX1paypWP
169fZwoxCU7NNbO8evWqkGiLpSOWD8o9og0AgMob1ky0yfWHhiH9hQg3btwoLUQYHR1NmpqaSse1
olRzxVxB4zI+Pp4MDg6WJvB3dXUtC99O8NdH/2uFqmXfvn1mBanwFw+EFiIojCKiLZaOWD4o94g2
AAAqb1gz0SbSXFlYlx/6aOXo3Nxc6ZhWWKrnLeRk99q1a2bxgtxpaJWmH35fX59xpaEwtMLz33//
LR3T0KgWQ1g3HVbApaVfokpxyCWH4on1CBZJR558UO4RbQAAVN7AMy+Ieg137drFw6fcI9oAYH1W
2nmcoQIN9npEPWBarGD9rKl30F20gA1Q3hFtAIBoAxrsGuDJkyfGl5qGNrUjwqVLl4x4A0Qbog0A
1r1wAxpswAYA0QYAiDagwQZsANEGAIBoAxpswAYQbQCAaAMabMAGANEGAFTewDMHbADRBgBA5Q0N
+czfvHnDg6bcI9oA6rkS49M4Hxrs+sbfkaFaeV5JOJOTk0lPT0/p/8+fP5sdJZRW+ZXr7e1NPn36
VDquXRiePn2KDSDaAIAKjGdO3snjWoarfVxnZ2dL/589e9Zs+2X3N9WersePHy8d17nyNYcNINoA
gMqLZ9+gzz609+idO3dMr4/2Fb1w4YLZ/sk9rr0/d+zYUSYm7F6k2ixem6prw3iL9gbVHqHaK3T/
/v3J1NRU7vjEwMCA2dtTx9UT5aJN6dVTpXibm5uTFy9elML1e1X1Vz1b2srKj0PhKG154lQ42mv1
wIEDy+6fnPcqfMXj8/z58+TIkSNlv6mHTWLNou/a69RF1+habB/RBkCBo+LCBhrQBkKiTb1BEl0S
EBIvFy9eLDsuYaVjdvP069evJyMjI6XeIm2cLiFlkWB7/Pix+a7hwb179+aOT2Hdvn27tBWVNq9X
z5TlypUryf379813bVm1b9++zDza/8+dO2fS7DI8PGzizhOnDaerq6tMgApdp96zNJQvCdSQaJN4
9Id1x8bGyu4Jdo9oA6DBBmyAPJvfbW+V+PLlS9km6zru9qKJlpYWIzZc4aGeM4t65aywKhqfBJ0r
aoQr+iTS/OMx0aYhR8Vhr9PfPXv2lPIVi9OGI5HY3d1ddp56H1+9epWanra2tmRmZqbsN4lbDYkq
PvX+SZypR9JF1+ha7B7RBkCBo+LCBhBtZb/7gkU9ZaHrfJHhX6PeNduj1t/fXyg+ffeHOt343HPz
ijZx6NAh0ysmxsfHzYT/vHG64ezevbs0R216ejo4/0xDuH5etejg5MmTJs6mpiZzr/yeNl2jYVrs
HtEGQIGj4sIGEG3B32OiLU04+edpHpztmbp8+XLu8NIEYSzuPKJNadEcOKG5bNpcPm+cbjiDg4Nm
uFWo1+zWrVuZ18XCFepV27lzZ6F8YveINgAabMAGGlS0vX79uvS/eoLcifFp10n0+MOjfm+RRWG7
YcTiU9hLS0uZ+VDvVNHhUYt6yTSXTUOjfn5CcbrhfPz40fSgLSwsmIUL/gIHl7SeNp8HDx4kp06d
KvtN8+roaUO0AQAVFyDalv2u1Z8SIxIYf/75Z5kLirTrNKnfzsvSZ3R01Igpi+adaQWp0IIEv+cu
FJ/CHhoaKoWt/3W+RQsRNKQo5M/MXYggkaR5alZQ+mnX4gL1armLDPLE6YejHrbffvvNLNAIoXlp
GkJ1UXol1MS7d+9MT6R/jubIMacN0QYAdVJxVcvz+2p4kF8PXukRbeW///XXX8mvv/5qFhBcunSp
zNlr1nXW5Yc+EjFyiWHR0KgWK2h4UILNCrg88Ym+vj7T+6beO809s6tWhXq2Tpw4YcJVHK7gkRjT
NbbXz0/74uKiOSbB6BOK0w9HCyn0W8zWtchAK1Nd7Dw4O6ctbcGGhlxZPYpoA4BAxaVVbJqrokZI
FbcaBrcxiR33sb6qNBm7aLpilWvWUFRRqhVOKMy8DcVaNiiItp93L+rh3kvQaag1hsSd22OXl87O
TiN8ufeINgAKXEbFpTdbDfPYIRL1JEiY5T3u4/qqqrZoq4XteaodJqIN0bYeUNlXr5y/KjYLvbQV
6X3WwoS8L3rYPaINoGEbr23btpVNGtZkYLfXKHbcjyPNO3teoRaqXLP208zy6C73Au5ehuoBPHr0
aK59OTXnRkNFmiskEarVdxractPiesuP5TvLm31ankMe6kMe92m8iuV5NXpbQ6x1fNVGtqsdC0IL
EFz04qb5b3nRuew9imgDgIIVlwSGxEilx2Mr2SoVbWnHQx7dNZSjSc3Wmaechlo/U7F4tG2PfFrZ
3kV5wXfznOYtP5TvvN7sYx7qQx73abzIM2ADiDaABqu47t69a0RGpcfXUrTFPLpLBMnVgYSPv0VR
UXyno763/FC+83qzj+Un5HGfxos8AzaAaANooIpLq8w0rKhenkqOr7Voi3l0t0JIWw0p7UXuhYY/
JU7lS0qr9WLpDOU7r2PUWH5CHvdpvMgzYAOINoAGqbgkxH7//fdUtwB5jldTtGXNO/PDyuN5vaen
x/R0FRFt2uxa12gDa3mQ1xDoWoi2PPnJ8rhP40WeARtAtAE0QMUlQSO3HvPz8xUdLyLaFEa1etpi
Ht216lVzxCS+igyPym+VG24ozXnyndebfSw/Lr7HfRov8gzYAKINoM4rrufPn5tNpbU9TSXHY/G4
k+ffv39vVmVWKtp8z+8hj+7qHevo6CgTRG/fvk0Nx0e+qOxqUbki0IKGWDpDXulD3uzd82Ie6kMe
92m8yDNgA4g2gDqvuHbt2rVsONI9N3Y8Fo8VFxr6U4+TREelos33/C6yPLrLl5zrQkDfdTwrHJdn
z56ZBQBKt4SSJv/H0hnySh/yZu+HFfJQH/K4T+NFngEbQLQBUHEBNkCeARtAtAEAFRdgA+QZsAFE
GwBQcQGiDbB7QLQBUHEBNkCeARtAtAEAFRdgA+QZsAFEGwAVF2AD5BmwAUC0AVBxATZAngEbQLQB
ABUXYAPkGbABRBsAFRdgA+QZsAFAtAFQcdVS3rWrgHYXaG1txQYaKM/amsxuVebz4MEDc3y17xti
ArtHtAEAFVeBvLt7o2IDjZNn/S5hpi3GXLR37IEDB9bkXiEmsHtEGwAUqrjevXtn9rjUhucSMM3N
zWU9ELYnSvtdatP1qampXMfEwMBAsnXr1mTLli1Jb29v2bHVClcbrZ8/f97s37lz585kYmIi2HCn
7af6xx9/mLB1T7RhuzaCd6/RHqA7duxIDh48SOO1jkXbtWvXklu3bpX9fvfu3aS/vz91r9mTJ0+W
7WcrOz169GjV7RKwe0QbABVX6u/qVRgfHzeNij4jIyNGkFjcnqjJyUmzkXqeYzdv3kxu375twvz+
/btppLSp+mqHOzw8nAwNDZnjHz9+TDo7OwttcH/9+nVzD+z9UHynT58uO//ChQvmmLuZO43X+hNt
8/PzSUdHR9nv3d3dydu3b1NFm563euf07NVDJ7ucnZ1dFbsE7B7RBkDFlQv1cFkk4O7fv596XuiY
5oipgXJxxddqhaveLw1xWaanpwuJtpaWlrLr9X379u1l57s9bzRe61e0CYk2iTSxsLBgXmL869zv
EmcSYBJkFy9eXDW7BOwe0QZAxZWKhvuuXLmSnDp1yogW91z1dOl/NUoaNnIJHVNvmT/86IrB1QpX
x13UkBYRbW5YaWGu5wYA0bb89xs3biR//vmn+W7FWEi0WYEmIb+4uLhqdgnYPaINgIprGXfu3En2
7duXjI2NJU+ePDFDQP65EnUPHz40Q0eXL1/OdSxN/KSJxWqH6zeOsUrbPxa7HtFWX6JN9q45ZhJR
EmMaMo09856eHlNmXNFWbbsE7B7RBkDFtQxNjF5aWir9r0Yr69zXr1/nPqYFBG64IaoZbnt7e9kw
1MzMTCHRpvD94dFNmzYh2mo4T0Web9rvWmyi3jbZTkyoj46Omrlreslxh0erbZeA3SPaAKi4lrF7
9+7SalE1JJpo7Z6rHgWtkhNaHOD2GISOaUK/nXitj/5X47ja4WpRxeDgYGnCd1dXV+GFCBoys+Gr
kW5qakK01bhoy1oJnEe0aZ6aeso0PBoSbeqVcxcuSKjZ+XDVtkvA7hFtAFRcy3j27JmZMC1hJLGk
BQDuuRqm1Dw3NWo6x4qp2DHR19dnevLUUyW3Iu5qy9UKV8iVg+Ycyf2CGuSiPTHW5Yc+Wjk6NzdX
V6ItS+jU6yf23D99+mRszbWjNNF24sSJMpcf+i77Ww27BEQbog2AiguwgbrLUyU9bYDdA6INgIoL
sIGfINqwe8AGEG0AVFyADZBnwAa4j9wCACouwAbIM2ADiDYAoOICRBsPHrvnJiDaAKi4ABsgz4AN
INoAgIoLsAHyDNgAog2AiguwAfIM2AAg2gCouKrOmzdveIg0XuQZsAFEGwAVV57rioRR5Lqsc93v
7v6fQOPVyHmu1TxNTk4mPT09pf+1F2vI8bF2jXB3mMAGEG0AUEXRthZx59l2CGi8yHPt0dramszO
zpb+f/jwodn6Kwude/DgQWwA0QYARSqugYEBsx+i9trs7e3NvM4PQ9dpr8Vt27YlIyMjwR6zDx8+
mH08N2/enBw9ejSZnp6OxpG1V+aBAweW5eH79+/Jrl27ks+fP/Owabyief727VvJHpubm5MXL16U
Hbf7z+q4Nn6X/bphjo2NmX1EZfv37t0zG8SrLGiv3MePH5ede+fOHXOuwrtw4ULy9evX0vF3796Z
HifFo2uVlr/++qvseu3Fu2PHjpLAcfOkfXl1nfZO1Qb2U1NThfJx+/btZPfu3aV9ft20x8J2ef78
eXLkyJGy3wYHB5MbN24En4+u0bXYPaINAHJUXNq4WhX3jx8/jPCZmJhIrl69GhVUuuby5cvmuo8f
PyYdHR1B8dXe3p4sLCyY8x88eJCcOXMmt2jzv3d1dS1rQJSes2fP8qBpvHLl+cqVK8n9+/dLPUL7
9u0rHZMA00uIbFUflREJPDdM2a/Ky99//23EmmxP/0v0SOi456oHSmJJYelF5+LFi6XjegEZHx8v
xaV4JdDc6yX0dMxuQO/myRVaGp7cu3dvoXxIMFoh56c9FLaP8iRx6nL8+HEjyvRCqHskAekj8eve
D+we0QYAgYpLDYoqdBe3cs4STlaEWdRzFhJcbs+a4lO8lYo2NbLd3d1laVYvxKtXr3jQNF658iyR
5tu9paWlxfTEWfRdPWVumH6PleZvZdmt24v35csX0yMcQj1bWXH54UvgWfG50nwUCdunra0tmZmZ
Kfvt119/Te7evVsq87du3TJi2UXX6FrsHtEGADkqLr1N+8OPfqOR9t1fGKBKOY/gcuOtVLQJDenY
+TMShGsxNwbRVl92n0c0xew19r++++LQj1vDnxIzp06dMkIrVnbc39QDZnvz+vv7V5SPImH7aPg1
SwS7dYSEnP+bhm+xe0QbAOSouNIq9lADlNXwFBVtruirRLRpvsy5c+fMdw356C0eaLyqIdrSjoVs
MSbaQuFrSFG9fhomfPLkiRkCLSLarOizvc+aslBpPoqEXbQeySsksXtEGwAEKi5NMHaHdvJW8hrS
0Fw2i4YmQ4LLXVWmYRp3iKgS0aa49XavIVrNmXEndwONVyzPTU1NmT1DKhP+sGLWS0Ye0fb69evS
/58+fTLzuyz67pa/+fn5wsLKonjcY0XzUSRsn7SeNg3FuguDFL8WWrhoHiA9bYg2AMhZcWmy8tDQ
UGmysv7XKrOYcPIXIuiakODShOTFxUVzvuIruhBBjYLm37iNkHrYfvvtNzNRG2i8iuRZw5Ea/hPy
FeYvRNCqR1smRkdHjcirVLSpbKiMKKw///zTTNC3aJjfrha187uKiDalW6s8hb+QoGg+ioTto3S7
81bFpUuXzMILG78WOCkNLnrZY04bog0AClRcfX195o1fb+FaTWZXqYVElNAQpXq5du7caVamhYY8
dVzn6hwJOH8id+y7Knxd68ahCd46h90SaLyK5lk9s/IhJiGieWS+4LCuMvTRy8Hc3FzFok2iTHO5
NLFfQka9bZZnz56ZhT9Kh0SSJv4XEW0avlT6rcsOK7IqyUfRsF20AlRl3L/HWlWrMivXKHpZ89G0
BlaPItoAYI0rLlXQsVVx1UbiUj0VQONVq3lulHuuFyi3hz4vnZ2dRhzyDBBtALCKFZfmq2iCsvXv
pjf60ETlaqN41UMYW9UGiDbu+dqgVaZFer01HOy6/uEZINoAYJUqLq10k5sNO/ShYR+Jt7VCc9w0
zMoCBBqvWs5zI+2Zq3lvmmOaF53L3qOINgCg4gJsALsHbADRBkDFBdgAeQZsANEGAFRcgA2QZ8AG
EG0AVFyADZBnwAYA0QZAxQXYAHkGbADRBgBUXIANkGfABhBtAFRcgA2QZ8AGANEGQMUF2AB5BmwA
0QYAVFyADZBnwAYQbQBUXIANkGfABhBtAEDFBdgAeQZsANEGAFRcgGgD7B4QbQBUXIANkGfABhBt
AEDlBTx78g48e0QbAJUY8My5B8AzB0QbQG1XZnwa5wPYPXYPiDYA4M0bAADRBgCAaAMAQLQBAKIN
AAAQbQCAaAMAQLQBACDaAAAQbQCAaAMAAEQbACDaAAAQbQAAiDYAAEQbACDaAAAQbQAAiDYAAEQb
ACDauAkAAIg2AEC0AQAg2gAAEG0AAIg2AEC0AQAAog0AEG0AAIg2AABEGwAAog0AEG0AAIg2AABE
GwAAog0AANEGAIBoAwBEGwAAog0AANEGAIBoAwBEGwAAINoAANEGAIBoAwBAtAEAINoAANEGAACI
NgBAtAEAINoAABBtAACINgBAtAEAINoAABBtAACINgBAtFHtAAAg2gAA0QYAgGgDAEC0AQAg2gCg
7sWa/wEAAEQbACDaAAAQbQAAKxVuAACAaAMARBsAAKINAADRBgCAaAMARBsAACDaAKAWhBsAACDa
AADRBgCAaAOA6ooXPo3zAQBAtAGsU8EGPHMAAEQbAI038OwBANEGADTagA0AAKINgAYbsAEAAEQb
AA02YAMAgGgDABpswAYAANEGQIMN2AAAINoAgAYbsAEAQLQBwNo02G/evOFGI9pqOv98+PCpzCk3
og2gRhrsiYmJZM+ePcmmTZuStra25PXr1xXFoeurmc7VFBmTk5NJT09PzQqa1UhPI4s2ehkBVlZm
KEEANdBo/fPPP0l7e3syPz+f/PjxIxkfH0/27dv30xrGtWpcW1tbk9nZWUQbgg0A8rxEczsAfn7D
derUqeTatWu5w3n06FGycePGZMOGDcn+/fuTqampUvh+13pqF7vzm0Ti+fPnk19++SXZuXOn6fEL
9bQNDAwkW7duTbZs2ZL09vbmSlcaz58/T44cObIsXR8+fEhOnz6dbN68OTl69GgyPT1dOv7u3bvk
2LFj5pjiaW5uTv7666/c8YfSHrsPiBfyDPCzyxAlCaAGGq/du3cXmosmYfL48WPzXUOMe/fuzYwj
JtqGh4eToaEhI1o+fvyYdHZ2Zoq2mzdvJrdv3zbnfv/+3Qibq1ev5kqXz8WLF5M7d+4sS5d6HBcW
FkwcDx48SM6cOVM6fuDAAdMLqWP6jIyMJDt27MgVfyztsfuAgCHPAIg2ABovIzYkMtRzpF6kEydO
JJ8+fcoMR0Ll/v37ueKIibaDBw8m3759K/2vnq0s0abhTIkaF1cYhdLlo3l7MzMzy9Ll9qwpLsUZ
Qr1qeeKPpT12HxAw5BkA0QZA42V+P3fuXLK0tGSEhXqFNGSahQSerpEQ6e/vX5Fok2B0UfxZok3n
+kOwrmgKpctH4tQXUWlp9dP38uXL5MqVK+b+tLS0lF0Tij+W9th9QMCQZwBEGwCNl5lH5fbySDDE
VoFKvDx8+DDp7u5OLl++XDXR5h93v7sip2i6fNLCSkurex80nKoFGmNjY8mTJ0+Sf//9d9k1WfHH
0h67DwgY8gyAaAOg8TIT7l0k2tQTlQe5BgktHPD/1wpV9zfNIXMFo4Yss8LT5H71BlaSLp+snjZ3
NanStWvXrjJx68bv5yUUfyztsfuAgCHPAIg2ABovMw9LHzvB/saNG2bOVxbqbdJKSaGJ924vkcSQ
VmBaAeJOzn///r1ZfemmQxP7BwcHSxPwu7q6MkXb9evXS5P19dH/hw8fzpUuH+XPnb9m49KK0sXF
RRO+4nIXImjBhl0tKlGlMNz0heKPpT12HxAwtZ3nRnIqjQPtxrufiDaAGmu8JNQ0kV7DgRJWb9++
zTxXQ4Caz6UhPwkTK1SEVkQqDDusaMWLzm1qajLn+umQu5Ht27cbdxiaTxfquevr6zM9XjadGqLM
ky4frR5VXP790W9Kh8KXgJMAtTx79swsHlDYEmgSum76YvGH0h67D4i21cvz169fjW2uhGo7la7l
e+jn9Weley3ideOwLn3s4qRqxV8r9xPRBtCAPQ7rhRcvXpT1dGEDjZlnuV85fvz4iu/LenIqXS/p
XOt0uKMGjVYmEW0ANNg/Hb0xN9pQD6KtHAl3DdvnuS9r4VR6bm7O+ANME5eaX/n58+dlx0JOn7U1
nYb7hZ2DqR1QhPwR6ngsjLJGO5JXfZc/Qk0lsD3OvtCRk2nle9u2bcbXYejea5qFdXatNOllK+1+
rsTxdehY3nyH0hlKWx7b+eOPP4xDbl0ve3V7//Pcb0QbAA12XaDK7bfffsMGGjjPWgWc976slVNp
zWf0d9NQw3z27NnUdIWcPv/+++/GSbS4d++eGYqz0wL0v4RGLIw0YZaVL32XQLHCwp/bqXxoVbXN
d0dHR/Dey72O9X2oVdnu9nrudStxfJ33uYbyHUpnkXvr/6+5rzrfXqtnZ59ZnvuNaAOgwQZsoO7y
nOectXIqbV3GuOj8V69e5c6zdTEjNzXywSj+93//1/gXtD4YtchGPXyxMIqKNrcnyD9udxxJy3ca
Ej/+Ku+8zyyv4+u8zzWU71A6i9xb/3/NkXXtRN817zXv/Ua0AdBgAzbQkKJtLZ1Ka7jLup+RsJFo
C5Hl9Flh2OFWDf3JFY11Y6NhOg2ZxsIoKtpC+fYn3cecSId6jdJ8JFbi+Drvcw3lO9a7lffe+v+n
+Xd044rdb0QbAA02YAMNKdps47sWTqXl/sX2kGk47NatW5lpijl91twxDUVasSZBKJc1rg/CWBjV
Em1Fd/7IK9pW4vg673OtVLQVubdF7QTRBkCDDdgAoi3CajuVlsjSxHMNJcoFjNySZBFz+qzVsf/z
P/9TGha1Q6TuVnWxMKol2uTbUHmzaMg3dO/liiXP8OhKHF/nfa6hfIfSWeTe+v+rd9QfHnV7KxFt
ADTYgA0g2lJYS6fSQj1sWihz4cKFYLpiTp/lg1HzoEZHR83/6rVTerUoIG8Y7nc/r0VEm78QQash
YwsRNHwpnj59mrkQYSWOr0PHiixEyEpnLG2h+6mFCHp+diGCnqHrUxDRBkCDDdgAoi2FtXQqLeQ2
Qr/F3NLEnD4/f/68zNWHnfzvOtCOheF+9/NadLhOYlV5lqsT5TvkmFg9jCdOnDDp0r13dzFxw12J
4+vQsbyiLZTOWNpC91NYlx/6SMjLLQyiDYDGq2poSOe///2vqYT0FqnKzB0SqQa+d/J6Qr0yeltH
tDV2njX3Sb009YzEjju3Dmq7DCHaAOqw8dJQj3xA2S59fdeWUNVktZxI1gJa8RdbLYhoq+88q9xo
2zN/NeN6Rz2LmvCv/MlhsHqR/EUBgGgDgEjjVU2v22krnmKrwDREIX9JrliR53QNoyhdvb29Zef7
XsRD51cSR558h7ygx8IOeWEXErka1kLANGaeZVOygdAChPWIVk+q/KkXXqtaL126ZMQbINoAIGfj
VW2v27anzaI5HIcOHQqmS5OtFbfdRF1pkGCyb+RyAqq5H1l5yXN+JXGE8h3ygh4LO+SFXcg9gDa1
R8CQZwBEGwCirUS1vW5reE9v0bYnTN+to9CsdPnha66av4Q+tG1QnvMriSOU75AX9FjYIS/swq4y
Q8CQZwBEGwCirUS1vW6rd0q9d7bnTqvk5CuqSLoUvz8MGtr6pej5lV6T16FmLOyQF3ah+6ZhVQQM
eQZAtAEg2oLiYyVetzVfxe1l0nfN0SmSrjQhGbqm6PmVXpNXtMXCFiEP7bHwETDkGQDRBtCAjVe1
vW77Ai3Wa5QWltLkehGPXVP0/EqvyesFPRa2S5qHds2Do6eNPAMg2gAQbWVU2+u2JvxrIr2Eh8Ib
Hh5Ozp8/XyhdStPQ0FApTfpfq1qzril6fqXX5PWCHgs75IVdaHsf5rSR5yLEnPDWe/y1mpZ6yBei
DaDGGq9qet2WmwIJN+vlW4It5LogKyz5qdK+fQpD8+Tsqs+sa4qeX8k1eb2gx8IOeWEX2mqI1aOr
n2eJ7p6enpoRkCt5PqGdBdaC1Yi/yP1yv/tpWUu7LxpXkfN/1jNGtAHQ4wABOjs7jbDDBlY3z1oI
ElrZvJ5E289+tqu5fVLR4z/zXqymaPtZ+UK0ASDaIAO5+1it7bkQbf+HnBf7O3XEeldjDpffvXtn
elU1r1PH5HTZbhZur5cbGeuU+ejRo5n7aYqQg2Y/jWkOp0NOs9NQfOodlpse+W7Mm56s+F1i90bT
CNQrr/i1L6l8G7phxY6XhEVKWrL286zEmXieZ5xFLA+hsNPyFUsLog0A0QarzG+//cbeo2uQZw0/
37lzp7BoCzlcPnDgQDI+Pl6ayyjhI5987vXt7e1mf14df/DgQXLmzJnUuGIOmmP5jDnN9lFcWsWs
c7VXcEdHR6H0xGwrdm8099XOA1X86m12w4wdz7u5+0qdied5xlnE8lA07Nj5iDYARBtgA3WRZy30
UK9mUdFWxNG08H3/uT1ramjdXlU3rJiD5lg+Y06zfayYtCidRdJTiW2590bbW7np9eOPHc8r2qrt
TDztGWcRy8NKwk47H9EGQIMN2EBd5FlDSr4IySPaYuFrLqJWFp86dcoIhNj1WY6sYw6aY+mIOc32
8Se5694USU8e2wrdGz9tafGHjucVbdVwJl70GefNQyVhh85HtAHQYAM2UBd5Tmu8VyraNNwqdy5y
eaPN0bViOHZ9lk/Eoj0mabuEFHn+MUFRiTNql9i9iaW3iBPwkGhbqTPxSp5x3riLhh07H9EGQIMN
2EBd5DlPT9v8/HyhBl0TzF2nymnXu6tVNVS2a9eu1LCKOGhOS1vMabaPhos1z8oiX4FF0hOzrdi9
0fCsm14NXRc5nle0rdSZeJ5nnEUsD0XDjp2PaAOgwQZsoC7yLJHi+9ZzVwq+f//eTEgvItq04tCu
3lODrDj867VidXFx0QhGTUrPWogQc9CcJkI1F8uKgpjTbB9/IYLiKpIeP36f2L3RhPrBwcFS/F1d
XYWOu9/9tPj5WIkz8TzPOItYHmJh+/mKnY9oA6DBBmygLvKs1aNaOehiVwpqKFANuZweFxFtz549
M5PzFYaGre7fv7/sesUptxnq3ZGA891NuIQcNPtoJad1aG0JOc1OQ4JCaZM7CqXT75kLpSctfpfY
vRHXrl0ziwKUBsVf5Lj73U9LlsuPSpyJ53nGIUJ5iIXt5yvPPUW0AdRZ41WtQr7ScFbzegQros3n
xYsXwZ6rRkc7frhDt0C9QS0KUEcNdi2LNkC0pSE3FvW6T2VR1Pvz8OHDkh829UZpuBQA0QZQQ41X
EY/vmkthvbnL+7Z6K7LCCcUT8wwuQt7g81xfaR4RbY2TZz13OTOGxKw+lB8xDb1pR4RLly4Z8QaA
aAOoYdEW8gYuf0CaNyH0Vq55FJWItphn8Jj39dj1K8kjoo08AwCiDWBdiLaQN3CJNN9NQiWiLeYZ
POZ9vahn8ZV6tUfAkGcARBsA1JxoCx0P9UitJJyi3tfzeBavNG0IGPIMAIg2AERbIJwi3teLentH
tCHaAADRBtBQok2+qyoZHi3q/TzmfT12PaKtcQSM7YlFtAEg2gAQbc5vWogwOTlpvj99+jRzIULM
s3zMM3jM+3rsekRb44k2/1PPecZNCSDaABBtUUEjh5snTpwwoqylpaVsGyD3vJhneRHzfh7zBh+7
HtEWqHwzhE69fupNFPu7DqymF/y1znetOPsGRBsAvSyADaxCnmqlp22t4gptiL7eRRu2jmgDACox
SJjT5vLu3TvTgytH0eoVlrNou/m2vS7khLkSB89jY2Omd1jOa+/du2eG/XV9moPnLOfSaeJUf7UJ
eshhtN1vU/nVVAPX7U2evISuL3KuzZvi0n0YGRnJFNkhZ955nh8g2gBosAEbqIM8HzhwwMyNtPMm
JR527NhRdl3ICXMlDp7PnDljnEX//fffRrScPXvW/O+HHXMundbT1tPTk5lWiUPlz+ZV4UsM5c1L
7Poi5ypf2h7LxtXR0ZEp2kLOvPM8P0C0AdBgAzZQp3l2Xc3EnDBX4uDZ751yV0gXcS6dJtpCadX8
Uzet+q4ev7x5iV1f5Fyt/F5YWMiMK68z7zzPDxBtADTYgA3USZ5fvnxpenNOnTplxEY1HUTH0hH6
P+ZcOs+ctpjfQzf9sbzEri9yrr+Iwo8rr1/ISp4fINoAaLABG1iHeb5z547pydE8M22WrtXJ1XQQ
vRLRFnMuXVS0xdK60uMrCatS0VbJ8wNEGwANNmAD6zDPmlPmDk/6DqBjQmglDp5j/8ecSxcVbQrP
H7J0e7zyOLsOXV/k3La2NjOXzfLq1avM+x5y5l3J8wNEGwANNmAD6zDPWmlpVxtKpEhMFBFtK3Hw
HPs/5lxaKyY1h82Ko1hadb1Wl9rwRkdHjSDKm5fY9UXO9RciKF+hhQhZzrwreX6AaAOgwa6Qol7d
8QKPaKtmnp89e2Ym92sITmJAqxSLOmGu1MFznv9DzqW1klS/2x6sPGm1bjj00WrOubm5QnkJXV80
LglExSP3Ioorq9cu5My7kucHiDYAGuwC8brf/QnJMdbCCzw2QJ5hbZEw27VrFzcC0QYAtSbaVpIe
Gl8EDHle/6g3Tz7XrA869cppuBQQbQCQs/FSxamhGDmn1KqsIsNERTyTZ+19GQsnywv858+fzVu6
3tZdNNdHE6ItWd7lsQHyDGuLVnrKL5x6zrUjwqVLl4x4A0QbAORovOQN3U5C1rwZVahFRFsRz+Sh
cIt6OLf/nzt3zkx+9vMkoSZi3uWxAfIMAIg2gHXReMn7uttTpf39ik7I9slyBFp0onAeh6Kzs7Om
t826BtDfPXv2lDzEx7zLYwPkGQAQbQDrovEq4uwy67e8nslj4RbxcO7+f+jQIdObJtRbp2FWN38h
7/LYAHkGAEQbwLoUbXnElftbEc/koXCLejh3/9fEZs2BE5rLpustjSrQEDCINgBEG0CdNV4dHR3J
p0+fSv/73tD963zP40U8k4fCLerh3P9fzjY1l01Doy4x7/LYAHkGAEQbwLpovB48eGBWj2Z5Q1dP
3OPHj8339+/fm6FH93gRz+Tud9+reyycmBd4LS6Qs05/kUHMuzw2QJ7XGzia5l4h2gAauPHSCkut
1Pz111+NcHLPlWCTcNMwo7ajefToUdnxIp7J3e++V/dYODEv8IuLi+aYu6+hJeRdHhtozDwXuRey
edmlFrXUAmvpaLrW8l6L90p1irbZQrQBwE9psBlSwgbI8//h9jY32nOstbyv9F6txr3TCna5SkK0
AQCiDRBtq5BnvwdYq481RK8eZVeopDl2FnZ/TQ3ba7jdupix12gltHqvbWOu37TIRjsCyKnsvXv3
zFC9eoB9YVSJo2mXWNqy8pp2j9Li8vOWJ868efcp4rx7mcjISL82tA/lv+izFUeOHEmeP3+OaAOA
tW+wi+4LCoi29S7aJAxs42ynBGSFIcEh5892nqSmF2hjdPf8CxculBxW29/OnDljHDz//fffRrCc
PXvW/O/HV6mj6bxpC+U1T0+Vn7c8cebNu0/Re5H2bP1jPT09mfmv5NkKidKLFy8i2gCABhuwgdUW
bW5vSqzhlw9BuyBG6Lt6kWLh+T027qrmSh1W+/9XmrYios2/vmicRfNe5F7kEW2h/Fdy/4RdPIVo
AwAabMAGVlm0FTme5vsv1DMXE1pp/1fqaLoaaSuSzkriLDrPrMi9yCPaQudXcv+Eet40pIpoAwAa
bMAGaki0rdQhdez/lTiarkbaigqsonEWEW1F78VKRVsl9y90LaINAGiwARv4iaJNDpv9ITR3HuhK
RdtKHE1XI21FBVbROIuItqL3oqhT7mrcP6H5efS0AQANNmADNSbaNFldKxDtZPXR0VHjw7Baom0l
jqarkbaiAqtonEVEW+xexJx/x5xyV+P+iVevXjGnDQDWb4ONJ3JsoF5Fm7BuIfTR6sK5ubmqibaV
OppeadoqEVhF4iwi2mL3Iub8O3avqnH/xK1bt1g9CgDrt8FeS6/t9CJyn8gz/Ew6OzvNgglEGwCs
y8ZrLTyRAwKGPMPPRsO263WbL0QbwDprvOzeghpe0CTcqakpMxwgp5Y+mmy7a9eu5PPnz4W9yOfx
RD4wMJBs3brVDEv09vZG05mWt9B52ACiDaDa/Pbbb+w9CgBr03i54mlyctLMHxFdXV3LBI9EmjyZ
2/CKeJGPeSKX53GFr8m/EocTExNmPkosnX5cofOwAUQbACDaANZt46UtYTS51+fhw4dJd3d32W/a
a0+rpGx4RbzIx87X8IIEm4sruLLS6YcTOg8bQLQBAKINYN02XuqN0jGJpv7+/rJjGsqcnZ0136en
p8s2SF4Np5b+sKrrnTyUTjec0HnYAKINABBtAOu68dKqJ9uzdvny5dLvg4ODyblz58x3LX3XsvbV
Em1p28fkTWfaFkBp52EDiDYAQLT9v/buL7KO9P8D+MVaq6KqVFRVrVIVERWh1qoVUXpRqxdrb3pR
e1Vq1YpVvYmqiCirqmpVqahVscKqFbWqVNWKXJSKql5UqYqqWEvkIiLq+fnM1xyTyTlnzmmS/pLs
68XRnHNmnvnTJ/m8zcwzA9uieM3MzKyYbm5uLrs55fv377MBAouLixsW2mLQQPHO5+2sZ6NtK0+n
DwhtgNAGW7Z4xQ0rY8RlKA8OCHGELUZHnT9/vq0Q9jF3Ih8dHa3diTze9/f3t7SexXaqtkcfsM2A
0AZbsnjFqcTu7u7abTjywJObmprK5i0/4aAqhH3MnciHhoayZw3GPDEyNR4O3cp6Ftup2h59wDYD
Qhtsy+IVwSkGJCDA2GYQ2oBNWrziNGUc/TIKU4CxzSC0AZu4eMV1acePH18xAAEBxjaD0AYoXugD
thmENvCLhz5gmwGhDRQv9AHbDEIboHihD9hu+P/63fFbBAoX+oBthy3wO+M3CBQt9IFPuv1eXl6t
vVb9/vgTCgo2+gCwBf5+2AWgYKMPAEIboGCjDwBCGyjY6AOA0AYo2OgDgNAGCjb6AIDQBgo2+gAg
tAGKNv7vAaENFG/8nwMIbbBZirjXf/fO5gBCG7DpwyoAQhsgtAEIbQBCG4DQBghtAAhtgNAGILQB
CG0AQhsgtAEIbQBCG4DQBiC0AQhtgNAGILQBCG0AQhsgtAEgtAFCG4DQBiC0AQhtgNAGgNAGCG0A
QhuA0AYgtAFCG4DQBiC0AQhtgNBmJwAIbYDQBiC0AQhtAEIbILQBILQBQhuA0AYgtAEIbYDQBiC0
AQhtAEIbgNAGILQBQhuA0AYgtAEIbYDQBoDQBghtAEIbQLthrfwCQGgDhDYAoQ1grcENAKENENoA
hDYAoQ1AaAOENgCENmAzBDcAhDZAaAMQ2oD1DS9e/50XgNAGWzSw4f8cQGgDxRv/94DQBija6AOA
0AYKNvoAgNAGCjb6ACC0AQo2+gAgtIGCjT4ACG2Ago0+AAhtwKcp2M+fP7ejhTZAaAM2omDPz8+v
2130v/jii3Vdz40KGevV7lrb+dTzC22A0AZbOLRNTk6m77//ftOEoa0ULIQ2QGgDPlnAGBkZSdev
X2+5nfv376fPP/88ffbZZ6mnpyc9fvy41n75SF29ZRY/+/DhQ/rxxx/Tzp070759+9L4+HjTI23D
w8Np165dqaOjIw0ODra0XlX7In4eGxtLBw4cyOaNNv7666/a90tLS+nMmTNpx44d6fDhw2lqaqph
O2vZ1qrta2V+oQ0Q2mAbh7bvvvsuHT9+PAsLEQguXrzYtJ1iqHnw4EE6ePBgw2VUBZlr166l0dHR
LJDMzc2lY8eONQxCN2/ezMJVTLu8vJyFlitXrrS0XlWh7dtvv02zs7PZ+2gj2spdunQpTUxMZD/H
Ucmurq6PCm1V21q1fVXzC22A0AbbPLTt3bs3/fbbb9nPEQhu3bqVBZVGOjs7ayGmahlVQaavry87
kpV7+vRpwyDU29ubrV9RMZg1W6+q0JYHtnrfR0grL/djQlvVtlZtX9X8QhsgtME2D21lERwiyDUS
R7GirQgZly9fXlNoKx7RypfdKAjFtOVTsHE6s5X1WkvYKq/jerVT3taq7auaX2gDhDb4j4W2UAwL
9UxPT2enCk+cOJEuXLiwbqGtWRCqWqdm67UZQ1u721c1v9AGCG2wzUPbnj170sLCQu19nIKLC+5b
MTMz0zS4lN+/efNmxWdfffXVilN+L168aNheDC6I25N8zHqtJWwdOnToo06PtrutVdtXNb/QBght
sM1D288//5yNWoxgEq+4+P3XX39t2E5c4xUjNUP5ov0YYRnXh+Xhojg44O3bt9kF/8X1uHv3bjZ6
Nb+4fmBgoGEQunr1au1C/HjF+/7+/pbWay2hLa7vi1Ov4dGjRw0HIqx1W6u2r2p+oQ0Q2mCbh7bF
xcV09uzZ7Ma4u3fvzoJDM3EKsru7u3Z7jDwohQh80U5+k908PMW0ccQqpi2vxy+//JId7YvRqzGC
slmgGhoayka4RvsRit69e9fSeq0ltMX+ifvYRZvRfgwAqDfdWre1avtamV9oA4Q22MahDX0AQGgD
BRt9ABDaAAUbfQAQ2kDBRh8AENpAwUYfAIQ2QMFGHwCENlCw0QcAoQ1QsNEHAKENFOzt4/nz5x/1
3XpMrw8AQhvwSQv2Vi7k+ZMX6m1L+bu1tCW0AUIboGBv0DZ5xJPQBghtsK0Kdvk5nGNjY+nAgQO1
Z3jmD0Fv5OLFi9nzMjs7O9OdO3faeq7n69evs2dsxoPmY1mHDx9O9+7da2l94rviq9h2ve+aLatR
WwsLC2n//v3Z80eLlpaWUk9PT+398PBw9jzQjo6ONDg4KLQBQhuw8aEtgs3s7Gz2Pn8IeiPXrl1L
IyMj6cOHD9nDzfv6+toKbUeOHEl3797N5o/XjRs3svDX6vqU22+27FaWVa+tc+fOpatXr67a7ghq
IR7cHsEy2lxeXk7j4+PpypUrQhsgtAEbG9rygNRKoe/t7V1xFGpqaqqt0FZPHFFrdX3aCW2tLKte
Wy9fvsyOtkUoC/Hvl19+WVuv2Af5d7mDBw8KbYDQBmxsaGun0JePwkV4abe96enpdOnSpXT69OnU
3d3d1vzthrZ2llV8/80332RH00IcrYujf8V9UD69WgyDQhsgtAGbLrS1215cA9fV1ZVu376dHj58
mJ1i3ajQ1u6yiu8nJyeza+BCXMsW8+c2a0AT2gChDYS2mq+//jr9+++/tfcvXrxo2t6bN29WfBYD
GObn5xt+v56hrd1lld/HYIi4li1OjRZFiCu2K7QBQhuw6ULbH3/8kY0ejdOic3NzaWBgYMX0xdGe
b9++zU4rFr+PIJSP4IzAd/To0bbWJ0aCxrVlMZqz6ruqZTVrK8Tggn379q0aZBCDFEZHR2sDHOJ9
f3+/0AYIbcDmCW0hRk/GKMy9e/dmoag4fT7aM04hHjp0KN2/f3/F90+ePMku2o9p4tTlxMREW+sT
ASpuipvfGLfZd1XLatZW+Oeff7LvIpyWDQ0NZUfy4vsIpnHqVWgDhDZgUxdswUAfAIQ2QGjD/w0g
tIGCvR7afeYnQhsgtAEKNvoAILSBgo0+AAhtgIKNPgAIbaBgow8ACG2gYKMPAEIbsBUK9vPnz+10
oQ0Q2oDNXrDLt/7YyOULI/YTILSBgr1OyxMYhDZAaAPWULDjeaD580F7enrS48eP06tXr9KRI0dW
Tbu8vJz279+fFhYWsvbGxsayB7HHvMWHw8d3xVf+2fXr1+tOnxseHk67du1KHR0daXBwsHI9621b
s+n0AX92AaENtmzBLoanBw8eZA9VDwMDA6sCT4S0s2fP1tqLh6PPzs5m7/OHwzdaXrw/efJkw+nj
wfPR/ocPH7JwOD4+nj3EvWo9y8tqNp0+4M8uILTBli3YnZ2daWJiYtXnk5OT6cSJEys+6+vrS8+e
Pau1lwewesuoF9qaTd/b25sFtqJi4Gq0nuV2mk2nD/izCwhtsGULdhyNiu8iNF2+fHnFd3Eq8+XL
l9nPT58+zUJbs/aqQluz6eMIWfm0apzibGU9i+00m04f8GcXENpgSxfs6enp2pG1Cxcu1D4fGRlJ
586dy34+c+ZMunXr1oaFtmJAa3c9y203mk4f8GcXENpgWxTsmZmZFdPNzc2lHTt2pPfv32cDBBYX
FzcstMWggfn5+Za2pbyejbatPJ0+YF8AQhts2YLd1dWVjbgM5cEBIY6wnTp1Kp0/f76tEBZhL65h
W1paamn6q1evptHR0ey6tnjF+/7+/pbWs9hO1fboAwBCG2zJgh2nEru7u2u34cgDT25qaiqbt/yE
g6oQFiM/4wa7+U12q6YPQ0NDaefOndk8MTL13bt3La1nsZ2q7dEHAIQ22JYFO4JTDEhAaAOENmCT
Fuw4TRlHv4zCFNoAoQ3YxAU7rks7fvz4igEICG2A0AYo2OgDgNAGCjb6AIDQBgo2+gAgtAEKNvoA
ILSBgo0+ACC0wX+5YJdvyovQBghtwEcW7AcPHqSTJ09uyHLzJyJs9zDTahvxpIdHjx4JbYDQBrRf
sHt7e9PLly//s0HhU65j7Oe+vj6hDRDagPYK9t9//53dQLc87e3bt9OePXvS7t270++//549wD2e
CxrP84wHsRcNDw+nXbt2pY6OjjQ4OLiineIrvH79OjvaFDfujbYOHz6c7t2713Tdq+aJtsfGxrLH
beXPHC2uYyvzv3r1Kh05cmTVspeXl9P+/fvTwsJC9hzTmD+W0dPTkx4/flx3/zabLsT+jv0utAFC
G9Bywf7pp5/SnTt3Vk37ww8/ZIHlzz//zMLa2bNns/cRhiKQ5G7evJkFpnjkVXw/Pj6ePSy+0XIj
GN29ezebPl43btxInZ2dTde9ap5YRoSy2dnZ7H15HVuZPwwMDKwKWLFtse2hGAbjlPLBgwfrbmez
6UIE4tjvQhsgtAEtF+yjR4+mFy9erJo2D0D5+/n5+bptxanVCEJFjcJMI3FEql3Fecrr28pyy/OH
ycnJdOLEiRXTxanMZ8+eZT9H0JuYmKjcv82mC7G/Y78LbYDQBrRcsOOUYTl0ladt9j6OKpVPg9YL
REXT09Pp0qVL6fTp06m7u7ulMNFsnnrzlz9rdf44xZpf3/f06dMV15/FUbOYNoLq5cuXGy6v2XQh
9necShbaAKENaLlg1zvK1U5oqzpKVp43TsV2dXVlpwgfPnyY3r17V5um3jVwVfO0EtramX9kZCSd
O3cu+/nMmTPp1q1bq8JffkTuwoULTUNivemKYVdoA4Q2oOWCvdYjbXGhffHUadVy4/q44vRv3ryp
DBNV81SFtnbmn5uby/bJ+/fvs8EVi4uLdddpZmamch3qTRfi2j9H2gChDWirYMe1VXEa8GNDW4wq
HR0drV3kH+/7+/tXhMK43mxpaSl7H6cf85Gb+bVdVWGiap6q0Nbu/HGE7dSpU+n8+fMrPo+jdTEy
NJQHOxTbaDZdiGvkXNMGCG1AWwU7RjHGCNCPDW1haGgoO5oVN9KNUZxx+jEXI0nj8/wmu0+ePMkG
KkSQiXATF+xXhYmqeapCW7vzT01NZZ+Vn+YQpzzjerj8tiJ5MCu30Wy6EKdcjR4FhDagrYIdAaV4
ZIyUhc44OrdRjh07lgU7oQ0Q2oC2CnaMcvSM0P+JU7xx5LDeqM/1EKdnY39vtj4AILTBFghtcd1V
XMPF/67BiycWNBqAsFaxnz17FBDaAAUbfQAQ2kDBRh8AhDZAwUYfAIQ2ULD9yukD+gAgtIGCjT4A
CG2Ago0+AAhtoGCjDwAIbaBgow8AQhugYKMPAEIbKNjoAwD+eoCCjT4ACG2Ago0+AAhtoGCjDwBC
G6Bo4/8eENpA8cb/OYDQBluhiHv9d14Aa/V/wrf1TMZjBMwAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-09-29 10:00:24 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADOCAMAAADbsfL2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-09-29 10:00:24 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAQoAAAGwCAIAAADe+LyNAAAQxUlEQVR42u3dsY4cVRbG8ZGQEIED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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-08-14 10:42:48 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Aminophylline versus placebo, outcome: 1.2 Return of spontaneous circulation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-09-29 14:14:44 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-06-25 13:53:17 +0100" MODIFIED_BY="Nicole Martin" NO="1">
<TITLE MODIFIED="2013-01-04 09:40:53 +0000" MODIFIED_BY="Nicole Martin">Search strategies 2009</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-25 13:53:17 +0100" MODIFIED_BY="Nicole Martin">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor heart arrest explode all trees<BR/>#2 heart next arrest*<BR/>#3 cardiac next arrest*<BR/>#4 cardiopulmonary next arrest*<BR/>#5 sudden next cardiac next death<BR/>#6 asystol*<BR/>#7 MeSH descriptor Cardiopulmonary Resuscitation explode all trees<BR/>#8 resuscitat*<BR/>#9 Bradyasystol*<BR/>#10 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)<BR/>#11 MeSH descriptor aminophylline explode all trees<BR/>#12 aminophyllin*<BR/>#13 MeSH descriptor Adenosine explode all trees with qualifier: AI<BR/>#14 adenosine next antagonist*<BR/>#15 adenosine next inhibitor*<BR/>#16 (Adenosine near/6 Block* )<BR/>#17 (#11 or #12 or #13 or #14 or #15 or #16)<BR/>#18 (#10 and #17)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE</HEADING>
<P>#1 "Death, Sudden, Cardiac"[Mesh] OR "Cardiopulmonary Resuscitation"[Mesh] OR "Heart Arrest"[Mesh] (29885)</P>
<P>#2 "sudden cardiac death" or "cardiopulmonary resuscitation" or "heart arrest" or "cardiac arrest" or asystol* (43164)</P>
<P>#3 #1 OR #2 (47970)</P>
<P>#4 "Aminophylline"[Mesh] OR "Adenosine/antagonists and inhibitors"[Mesh] (4723)</P>
<P>#5 Aminophylline (4984)</P>
<P>#6 #4 OR #5 (5816)</P>
<P>#7 #3 AND #6 (57)</P>
<P>#8 #3 AND #6 Limits: Humans (41)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<P>#1. 'sudden death'/exp OR 'resuscitation'/exp OR 'heart arrest'/exp (85,049)</P>
<P>#2. 'sudden cardiac death'/exp OR 'sudden cardiac death' OR 'cardiopulmonary resuscitation'/exp OR 'cardiopulmonary resuscitation' OR 'heart arrest'/exp OR 'heart arrest' OR 'cardiac arrest'/exp OR 'cardiac arrest' OR asystol* (94,133)</P>
<P>#3. #1 OR #2 (94,133)</P>
<P>#4. 'aminophylline'/exp OR 'adenosine receptor blocking agent'/exp (18,617)</P>
<P>#5. 'aminophylline'/exp OR aminophylline (12,594)</P>
<P>#6. #4 OR #5 (19,106)</P>
<P>#7. #3 AND #6 (268)</P>
<P>#8. #7 AND [humans]/lim(204)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL</HEADING>
<P>S1 (MH "Death, Sudden, Cardiac") or (MH "Resuscitation, Cardiopulmonary+") or (MH "Heart Arrest) (7943)</P>
<P>S2 "sudden cardiac death" or "cardiopulmonary resuscitation" or "heart arrest" or "cardiac arrest" or asystol* (6080)</P>
<P>S3 S1 or S2 (9378)</P>
<P>S4 (MH "Aminophylline") or (MH "Adenosine/AI") (111)</P>
<P>S5 aminophylline (130)</P>
<P>S6 S4 or S5 (149)</P>
<P>S7 (S4 or S5) and (S3 and S6) (15)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS</HEADING>
<P>Search words included combinations of:</P>
<P>asystole (405) or bradyasystole (0) or cardiac arrest (399) or heart arrest (399)</P>
<P>AND</P>
<P>aminophylline (77) or (adenosine AND antagonist) (10) </P>
<P>Yeild: 1 citation </P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-09-29 14:14:44 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-07-26 13:18:37 +0100" MODIFIED_BY="[Empty name]">Search strategies 2014</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-26 13:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL </B>(search restricted to years 2012-2014)</P>
<P>#1 MeSH descriptor Heart Arrest explode all trees</P>
<P>#2 (heart next arrest*)</P>
<P>#3 (cardiac next arrest*)</P>
<P>#4 (cardiopulmonary next arrest*)</P>
<P>#5 "sudden cardiac death"</P>
<P>#6 (asystol*)</P>
<P>#7 MeSH descriptor Cardiopulmonary Resuscitation explode all trees</P>
<P>#8 (resuscitat*)</P>
<P>#9 (Bradyasystol*)</P>
<P>#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)</P>
<P>#11 MeSH descriptor Aminophylline explode all trees</P>
<P>#12 aminophyllin*</P>
<P>#13 MeSH descriptor Adenosine explode all trees</P>
<P>#14 (adenosine next antagonist*)</P>
<P>#15 (adenosine next inhibitor*)</P>
<P>#16 (Adenosine near/6 Block* )</P>
<P>#17 (#11 OR #12 OR #13 OR #14 OR #15 OR #16)</P>
<P>#18 (#10 AND #17)</P>
<P>
<B>MEDLINE (OVID)</B>
</P>
<P>Cochrane sensitive-maximising RCT filter applied (Handbook 2011)</P>
<P>1. Heart Arrest/</P>
<P>2. heart arrest*.tw.</P>
<P>3. cardiac arrest*.tw.</P>
<P>4. cardiopulmonary arrest*.tw.</P>
<P>5. "sudden cardiac death".tw.</P>
<P>6. asystol*.tw.</P>
<P>7. exp Cardiopulmonary Resuscitation/</P>
<P>8. resuscitat*.tw.</P>
<P>9. Bradyasystol*.tw.</P>
<P>10. or/1-9</P>
<P>11. exp Aminophylline/</P>
<P>12. aminophyllin*.tw.</P>
<P>13. Adenosine/ or Adenosine A1 Receptor Antagonists/ or Receptor, Adenosine A1/</P>
<P>14. adenosine antagonist*.tw.</P>
<P>15. adenosine inhibitor*.tw.</P>
<P>16. or/11-15</P>
<P>17. randomized controlled trial.pt.</P>
<P>18. controlled clinical trial.pt.</P>
<P>19. randomized.ab.</P>
<P>20. placebo.ab.</P>
<P>21. drug therapy.fs.</P>
<P>22. randomly.ab.</P>
<P>23. trial.ab.</P>
<P>24. groups.ab.</P>
<P>25. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24</P>
<P>26. exp animals/ not humans.sh.</P>
<P>27. 25 not 26</P>
<P>28. 10 and 16 and 27</P>
<P>29. (201203* or 201204* or 201205* or 201206* or 201207* or 201208* or 201209* or 201210* or 201211* or 201212* or 2013* or 2014*).ed.</P>
<P>30. 28 and 29</P>
<P>
<B>EMBASE (OVID)</B>
</P>
<P>Cochrane RCT filter (Handbook 2011)</P>
<P>1. Heart Arrest/</P>
<P>2. heart arrest*.tw.</P>
<P>3. cardiac arrest*.tw.</P>
<P>4. cardiopulmonary arrest*.tw.</P>
<P>5. "sudden cardiac death".tw.</P>
<P>6. asystol*.tw.</P>
<P>7. exp Cardiopulmonary Resuscitation/</P>
<P>8. resuscitat*.tw.</P>
<P>9. Bradyasystol*.tw.</P>
<P>10. or/1-9</P>
<P>11. exp Aminophylline/</P>
<P>12. aminophyllin*.tw.</P>
<P>13. Adenosine/ or Adenosine A1 Receptor Antagonists/ or Receptor, Adenosine A1/</P>
<P>14. adenosine antagonist*.tw.</P>
<P>15. adenosine inhibitor*.tw.</P>
<P>16. or/11-15</P>
<P>17. random$.tw.</P>
<P>18. factorial$.tw.</P>
<P>19. crossover$.tw.</P>
<P>20. cross over$.tw.</P>
<P>21. cross-over$.tw.</P>
<P>22. placebo$.tw.</P>
<P>23. (doubl$ adj blind$).tw.</P>
<P>24. (singl$ adj blind$).tw.</P>
<P>25. assign$.tw.</P>
<P>26. allocat$.tw.</P>
<P>27. volunteer$.tw.</P>
<P>28. crossover procedure/</P>
<P>29. double blind procedure/</P>
<P>30. randomized controlled trial/</P>
<P>31. single blind procedure/</P>
<P>32. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31</P>
<P>33. (animal/ or nonhuman/) not human/</P>
<P>34. 32 not 33</P>
<P>35. 10 and 16 and 34</P>
<P>36. (201203* or 201204* or 201205* or 201206* or 201207* or 201208* or 201209* or 201210* or 201211* or 201212* or 2013* or 2014*).dd.</P>
<P>37. (2012* or 2013* or 2014*).em.</P>
<P>38. 36 or 37</P>
<P>39. 35 and 38</P>
<P>
<B>CINAHL (EBSCO)</B>
</P>
<P>S1 (MH "Heart Arrest+")</P>
<P>S2 "heart arrest*"</P>
<P>S3 "cardiac arrest*"</P>
<P>S4 "sudden cardiac death"</P>
<P>S5 asystol*</P>
<P>S6 (MH "Resuscitation, Cardiopulmonary+")</P>
<P>S7 resuscitat*</P>
<P>S8 Bradyasystol*</P>
<P>S9 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8</P>
<P>S10 (MH "Aminophylline")</P>
<P>S11 aminophyllin*</P>
<P>S12 (MH "Adenosine+")</P>
<P>S13 "adenosine antagonist*"</P>
<P>S14 "adenosine inhibitor*"</P>
<P>S15 Adenosine N6 Block*</P>
<P>S16 S10 or S11 or S12 or S13 or S14 or S15</P>
<P>S17 S9 and S16</P>
<P>S18 (singl* blind*)</P>
<P>S19 (doubl* blind*)</P>
<P>S20 (tripl* blind*)</P>
<P>S21 (trebl* blind*)</P>
<P>S22 (trebl* mask*) or (tripl* mask*) or (doubl* mask*) or (singl* mask*)</P>
<P>S23 (randomi?ed control* trial*)</P>
<P>S24 (MH "Random Assignment")</P>
<P>S25 (random* allocat*)</P>
<P>S26 (MH "Placebos")</P>
<P>S27 (MH "Quantitative Studies")</P>
<P>S28 (allocat* random*)</P>
<P>S29 S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28</P>
<P>S30 S17 and S29</P>
<P>S31 EM 20120301-20141116</P>
<P>S32 S30 and S31</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies (based on 8 references) included in qualitative synthesis&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;22 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;264 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;264 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;285 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;21 records identified through online searching (e.g. Google)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;39 records excluded&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;39 records identified through database searching in November 2014&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;242 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;14 full-text articles excluded:&lt;/p&gt;&lt;p&gt;Not designed prospectively (9)&lt;/p&gt;&lt;p&gt;Mixed comparisons (5)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 study awaiting classification (unable to get additional data and methodological information from author)&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>